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Introduction
Tumor necrosis factor alpha (TNF-a) is a naturally occurring glycoprotein which displays an
intriguing variety of biological functions. On the one hand it is cytotoxic for tumor cells, and as such
has been used in the treatment of cancer since, with molecular cloning, it became available in sufficient
quantities. On the other hand TNF-a is a central mediator in the metabolic changes observed during the
systemic response to infection, be it bacterial, viral or protozoal. It is identical to ‘cachectin’, the
lipoprotein lipase inhibitor that was isolated by Cerami and coworkers from the serum of severely
wasted rabbits, infected with Trypanosoma brucei [1]. Administration of recombinant TNF-a (r-TNF-
a) to experimental animals induces a clinical picture that is virtually identical to the septic shock
syndrome [2].
In view of these potent pro-inflammatory actions of TNF-a, it is hardly surprising that systemic
toxicity has been a notorious drawback of cancer treatment with r-TNF-a. Early clinical trials have
been disappointing due to both a lack of objective tumor response and serious systemic side effects.
Treatment related fatalities have been described. It was generally felt that higher concentrations of r-
TNF-a were needed to achieve significant anti-tumor effect, but that toxicity would preclude the use of
such high dosages. A breakthrough in the clinical use of r-TNF-a occurred in 1992 when the first
report on isolated limb perfusion with high dose r-TNF-a was published [3]. With this technique, very
high concentrations of r-TNF-a were achieved locally, while systemic toxicity seemed to be
manageable. An impressive clinical response rate was obtained in patients with unresectable sarcomas
and melanomas of a limb [4,5].
When isolated limb perfusion with r-TNF-a was introduced at the University Hospital in
Groningen, it became readily apparent that toxicity, though indeed manageable in a modern Intensive
Care Unit, was still considerable. During perfusion and in the immediate post-operative phase, most
patients developed a sepsis syndrome characterized by high fever, systemic vasodilation and low
bloodpressure. The studies presented in this thesis were conducted to explore the exact nature of this
toxic response and, if possible, to clarify its mechanism.
Chapter I summarizes what is known of the side effects of treatment with r-TNF-a in general. It
also offers some guidelines for the treatment of patients undergoing isolated limb perfusion with r-
TNF-a, and it suggests a number of experimental strategies that may prove useful in the future.
Chapter II defines the clinical response as it is seen in post-perfusion patients and relates the severity of
symptoms to the amount of leakage of r-TNF-a from the perfusion circuit to the systemic circulation.
In chapter III the effects of leakage of r-TNF-a on systemic coagulation variables are studied, in
particular the added influence of pretreatment with interferon gamma (IFN-g). Chapter IV is about the
impact of isolated limb perfusion with r-TNF-a on the human fibrinolytic system. In chapter V renal
effects of this type of treatment are studied in some detail. Finally, in chapter VI, the role of nitric
oxide as a possible mediator of TNF-a-induced systemic vasodilation is investigated.Introduction
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Summary
The purpose of this chapter is to familiarize intensive care staff with the concept of isolated limb
perfusion with recombinant human tumor necrosis factor alpha (r-TNF-a), a new modality in cancer
treatment, that has attracted considerable attention. The systemic toxicity of this type of treatment, and
of cancer therapy with r-TNF-a in general, is reviewed. This review is based on Phase I and Phase II
trials published in the English language, along with supportive documentation and data on 64 patients
treated with r-TNF-a in our own institution. Guidelines are offered for the successful management of
this type of patient.
Treatment with r-TNF-a results in a characteristic clinical syndrome, which resembles the sepsis
syndrome. Hypotension and respiratory failure are the main features of this syndrome. Toxicity is
largely independent of the route of administration. Very high serum concentrations of TNF-a, if
shortlived, can be less toxic than sustained low serum concentrations. Treatment of patients who have
undergone isolated limb perfusion with high dose r-TNF-a is feasible and effective in a modern ICU
setting, even if high serum concentrations of TNF-a , due to leakage from the perfusion circuit, cannot
be avoided. Most patients can be discharged from the ICU within 24 hours.Side effects of treatment with TNF-a
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Introduction
Cancer treatment with bacteria or bacteria-induced serum factors is not new. Late in the previous
century, the surgeon William Coley reported considerable success in the treatment of advanced cancers
with injections of live bacteria or bacterial extracts, although at the cost of serious morbidity [1-2].
Later, Shear and coworkers could show that endotoxin, a part of the cell wall of Gramnegative
bacteria, was indeed capable of inducing hemorrhagic necrosis in laboratory animals with transplanted
tumors [3]. Since endotoxin did not kill tumor cells in vitro, the possibility of an intermediate cytotoxic
host factor released by the administration of endotoxin was suggested. In a series of elegant
experiments Carswell and coworkers were able to demonstrate the presence of such a substance in the
serum of BCG-infected mice treated with endotoxin [4]. When this serum was intravenously
administered to animals bearing a subcutaneous transplant of a murine sarcoma, visible necrosis of the
tumor was observed. Accordingly, the active substance was named tumor necrosis factor (TNF). In the
mid-eighties the DNA for human tumor necrosis factor was cloned and, with recombinant techniques,
large amounts of human TNF became available for research purposes [5-6]. Since TNF had shown in
vitro anti-tumor activity against a number of different cell lines, while showing no effect on human
fibroblasts, there was considerable interest to try this new drug in clinical trials in various types of
neoplastic disease. Between 1987 and 1991 a series of Phase I and Phase II trials was carried out [7-
43]. Unfortunately, none of them showed unequivocal clinical benefit. As toxicity turned out to be
pronounced and lethal complications of systemic treatment with TNF were reported, interest in this
new drug waned as quickly as it had been aroused. Recently a revival of TNF as antineoplastic drug
was introduced by Lejeune and coworkers who combined high-dose human recombinant TNF-a (r-
TNF-a) with an alkylating drug in a system of isolated regional perfusion [44]. A response rate of 87%
was seen in patients with locally irresectable sarcoma of a limb [45]. Later, encouraging results with
this technique were also described in patients with melanoma [46]. Toxicity was considered to be
acceptable, although all patients needed intensive care after the procedure [47-48]. This technique of
regional perfusion with r-TNF-a in combination with other antineoplastic drugs is rapidly gaining
acceptance as a valuable alternative in the treatment of several types of cancer. Post-perfusion patients
will find their way to the ICU in increasing numbers and intensivists should be thoroughly familiar
with the serious side-effects of treatment with r-TNF-a to be able to provide proper care.
TNF-a a toxicity in vivo
TNF-a is generally considered to be the key mediator in the mammalian response to bacterial infection.
It is mainly produced by stimulated macrophages and monocytes but many other cells have been
reported to be able to synthesize TNF-a. It is a strong pro-inflammatory agent that will affect the
function of almost any organ system, either directly or by inducing the formation of other cytokines like
IL-1, or prostaglandins. TNF-a, which naturally occurs in a trimeric form, exerts its influence on cells
by binding to a specific receptor. Two types have been identified: the smaller 55 kilodalton TNF-R55
receptor, present on virtually all nucleated cells and the larger 75 kilodalton TNF-R75 receptor, mainly
present on lymphocytes. The extracellular portions of these receptors can become separated from the
cellmembrane by proteolysis, and can bind and inactivate TNF-a in the circulation. They are referred
to as soluble receptors. Their shedding from cellmembranes is upregulated by TNF-a itself. If injected
in small amounts, TNF-a is bound rapidly to tissue receptors and degraded in the cells. If administeredChapter I
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in larger amounts it is broken down and partially cleared by the kidneys, and, to a lesser extent, by the
liver. The serum half-life of TNF-a is dose-dependent: at doses of 25 mg/m
2 a serum half-life of 13 min
has been described , increasing to 26 min at higher doses [9].
If administered intravenously to laboratory animals it causes a clinical picture very similar to septic
shock. Excessive vasodilation will cause hypotension, acidosis and oliguria with renal failure.
Increased capillary permeability will result in edema which in the lung will interfere with gas exchange.
Activation of the clotting system may lead to a disseminated intravascular coagulopathy. Liver cell
necrosis may occur. Even small doses of TNF-a can cause death in susceptible animals. If
administered in smaller quantities to human volunteers it causes fever, headache, anorexia, myalgia,
hypotension, capillary leak syndrome, increased rates of lipolysis and skeletal muscle protein
degradation [49].
Toxicity of TNF-a a in the treatment of cancer: general remarks
Although the exact mechanism, leading to tumor cell necrosis in vivo, is still largely unknown, TNF-a
has been tried for almost any kind of malignant disease. It has been administered subcutaneously,
intramuscularly and intravenously in many different dose regimens. It has also been used locally, for
instance in tumors of the bladder and in ovarian carcinoma. Intratumoral application of r-TNF-a has
been studied extensively and has even been tried in the treatment of brain tumors [23, 24, 40, 41].
Recently, combined treatment of r-TNF-a with alkylating drugs in an isolated perfusion model has
received considerable attention [44, 45, 46]. This technique can only be applied with tumors of a limb.
After dissection and cannulation of femoral, popliteal or axillary vessels, a perfusion circuit is
established using a roller pump and a membrane oxygenator (Fig 1). The system is primed with red
blood cells, a colloid solution and heparin and kept at a temperature of 39
o C.
Fig.1 Set-up of isolated limb perfusionSide effects of treatment with TNF-a
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After equilibration, up to 4 mg of r-TNF-a is infused into the perfusion circuit. r-TNF-a is usually
combined with an alkylating agent such as melphalan to obtain maximal anti-tumor efficacy. Some of
these patients are pretreated with recombinant interferon gamma (r-IFN-g) to enhance the sensitivity of
the tumor to r-TNF-a. Human r-IFN-g increases the number of TNF-receptors on human tumor cells
[50, 51]. Additionally, r-TNF-a and r-IFN-g show synergy in antitumor effects on human tumor cells
[52].
Subcutaneous and intramuscular routes of administration have been largely abandoned because of
unacceptable local side effects such as soreness and ulceration [12]. Instillation of the drug into body
cavities (intravesical, intraperitoneal ) does not usually lead to detectable serum levels of TNF-a.
Although systemic side effects of this type of treatment are reported to be mild by some [25, 43],
others have observed severe systemic toxicity with fever, influenza-like symptoms and prolonged
malaise [21]. Intralesional application of r-TNF-a will results in highly variable plasma levels of this
cytokine [27], but most reports show plasma concentrations comparable to what is observed after
intravenous dosing [23, 24, 27]. Again, systemic side effects may be severe, with intolerable rigors,
fatigue and tachycardia [40].
Thus, it appears from the literature that all routes of administration of r-TNF-a can cause serious
systemic side effects. Severe toxicity has been reported with low plasma concentrations of TNF-a [42],
while very high concentrations of this cytokine are relatively well tolerated if its presence in the
systemic circulation is short-lived. For example, toxicity in a study where r-TNF-a was infused over
24 hours, resulting in peak plasma concentrations of 8000 ng/L [33], was more severe than in a study
where a 30 min. infusion of the drug led to peak levels of 300.000 ng/L [36]. Systemic toxicity seems
to be determined mainly by the length of time that elevated concentrations of TNF-a can be found in
the circulation. This is in keeping with the observation by Pinsky and coworkers that persistence of
TNF-a and interleukin-6 concentrations, rather than peak concentrations of cytokines, predicts a poor
outcome in septic shock [53]. On the other hand, the promising results of isolated limb perfusion with
very high doses of r-TNF-a suggest that the effects of this drug on the tumor are dependent on high
levels of TNF-a, and that, with such high levels, an exposure time of 90 min is sufficient to destroy
virtually all malignant tissue. It follows that, generally speaking, short courses with high dose r-TNF-a
hold most promise for the future, from the point of efficacy as well as from the point of toxicity.
Regional perfusion techniques were originally developed to avoid systemic toxicity. Ideally the drug
would not spread beyond the limb that was being perfused. Indeed, perfusions with melphalan alone
showed little systemic toxicity. However, it appeared that adding r-TNF-a to the perfusate invariably
induced a sepsis syndrome, probably due to leakage of r-TNF-a into the systemic circulation [44, 47,
48, 54, 55]. We were able to demonstrate plasma levels of TNF-a in these patients of up to 267000
ng/L at the end of perfusion [56]. For comparison, in meningococcal disease and/or septicemia all
patients with TNF-a levels over 100 ng/L died [57]. In other types of septic shock median TNF-a
levels of 120 ng/L have been reported [58]. TNF-a levels in perfused patients were very high initially
but fell rapidly: 12 hours postperfusion TNF-a levels had returned to baseline values [48].
It is still unclear whether the very high levels of systemic TNF-a, measured in perfusion patients,
represent free TNF-a or neutralized TNF-a, bound to soluble receptors. The latter possibility would
explain why clinical signs and symptoms in these patients are less severe than anticipated from the very
high serum TNF-a levels. Thom and coworkers have reported a moderate increase in the soluble 55 kdChapter I
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TNF receptor (TNF-R1) during perfusion with r-TNF-a, possibly representing an upregulation of
receptor shedding [54]. With melphalan alone, the rise in serum TNF-R1 was less pronounced.
Interleukin 6 (IL-6) concentrations rise significantly during isolated limb perfusion with r-TNF-a and
may contribute to toxicity [54]. Interleukin 1 (IL-1), which can act synergystically with TNF-a, seems
to be less important in this setting. The role of anti-inflammatory cytokines like interleukin 4 (IL-4) and
interleukin 10 (IL-10), which could mitigate the toxic effects of TNF-a, remains to be elucidated.
Toxicity of r-TNF-a treatment is variable and not always dose-dependent. Hepatic and
cardiovascular toxicity have been generally found to increase with increasing dose, but constitutional
symptoms like fever, chills, rigors and prostration are probably not dose-related. The maximum
tolerated dose of r-TNF-a, administered intravenously over 30 min, is reported to be between 100 and
300 mg/m
2 [7-10, 12, 13, 14, 17, 29, 39]. Signs of late toxicity are notoriously absent in all reports.
Specific signs and symptoms of toxicity in patients treated with r-TNF-a a
Constitutional
As was stated before, symptoms after treatment with r-TNF-a by any route are variable and
individually determined. However, virtually all patients will experience constitutional symptoms. This
influenza like syndrome is characterized by fever up to 40
0 C, chills, rigors, headache, back pain,
fatigue, prostration and malaise. These symptoms are probably not dose-related [13, 17, 19, 30-31]
and will disappear spontaneously even if treatment with r-TNF-a is continued without dose
adjustment.
Cardiovascular
Cardiovascular toxicity is usually dose-limiting. A fall in blood pressure is observed in many patients
[7-10, 12, 14-20, 22, 23, 27-28, 30-33, 37-38, 55], sometimes preceded by a short period of
hypertension [33]. Hypotension can be severe with systolic blood pressures < 60 mm Hg. Volume
resuscitation and inotropic support of the circulation are frequently necessary to maintain acceptable
tissue perfusion. Sinus tachycardia is common but other rhythm disturbances are rare [37]. In one
patient a transmural myocardial infarction soon after starting treatment with r-TNF-a has been
described [7]. Excessive production of nitric oxide, a potent vasodilator, by cytokine-inducible nitric
oxide synthase is believed by many to be the underlying mechanism. TNF-a can induce nitric oxide
synthase in vascular smooth muscle cells from rat aorta in vitro [59]. In mice the administration of
anti-TNF-a antibodies markedly reduces endotoxin-induced shock and nitric oxide synthesis in vivo
[60]. Kilbourn and coworkers have induced hypotension in dogs by administering recombinant human
TNF-a. N
G-monomethyl-L-arginine, a competitive inhibitor of nitric oxide formation from L-arginine,
completely reversed this fall in blood pressure, which reappeared after the administration of excess L-
arginine. The authors conclude that excessive nitric oxide production mediates the hypotensive effect of
TNF-a [61]. Whether the same mechanism applies to humans remains to be seen. In a series of 8
patients treated with hyperthermic isolation perfusion with r-TNF-a we have measured nitric oxide
metabolites in plasma. All patients developed vasodilation and hypotension, secondary to a pronounced
leak of r-TNF-a from the perfusion system to the systemic circulation. However, we were unable to
demonstrate any elevation in plasma nitrite or nitrate [56]. Other mechanisms, not involving the nitric
oxide pathway, are therefore likely to play a role in the generation of hypotension and septic shock in
the setting of r-TNF-a perfusion. The existence of a nitric oxide independent pathway to explainSide effects of treatment with TNF-a
15
cytokine-induced vasodilation in humans was already suggested by Beasley and coworkers [62].
Alternatively, cyclooxygenase products like prostacyclin could also play a role [63].
Respiratory
Respiratory compromise is common after treatment with r-TNF-a [2, 3, 7-10, 13, 18, 23, 30-33, 39,
64, 65] and may range from slight symptoms of tightness of the chest and tachypnea to severe
respiratory distress requiring mechanical ventilation. Administration of r-TNF-a has been shown to
affect pulmonary function parameters: it decreases vital capacity, capillary blood volume, diffusing
capacity of the alveolo-capillary membrane and transfer capacity for carbon monoxide [64]. It is
unclear whether these effects are dose-related [48, 64]. Significant reductions in these parameters are
observed 1 week after isolated limb perfusion with r-TNF-a and melphalan. Eight weeks after the
perfusion procedure, they have returned to pre-treatment values. Treatment with r-TNF-a also
increases pulmonary permeability, which could explain the transient pulmonary infiltrates described in
the original publication by Eggimann [47, 66]. A relationship between the Lung Injury Score (Murray)
and TNF-a levels has been described [48].
Renal
Renal toxicity is surprisingly mild. In most series renal toxicity does not exceed moderate proteinuria
and minimal elevation of serum creatinine [7, 9, 13, 17, 20, 31-33, 37-38, 55]. Others have reported
more serious renal symptoms, such as a marked reduction in creatinine clearance, oliguria and elevated
tubular enzyme excretion [12, 14, 23, 27, 28, 30, 67]. Whether renal toxicity in this setting is a
consequence of inadequate perfusion pressures or a direct toxic effect of r-TNF-a, remains to be
determined [23, 27, 67]. Even in patients who could be kept normotensive throughout the perfusion
procedure and during their postoperative stay in the ICU, a temporary decrease in proximal tubular
function was observed [67]. This may represent a direct toxic effect of TNF-a.
Hepatic
Many patients will develop a significant rise in either bilirubin or ASAT and ALAT or both [7-9, 14-
16, 18-20, 22, 23, 27, 28, 30, 32-35, 37-38, 55]. Liver cell damage can be dose-limiting [8-9, 18, 20,
32], but is usually rapidly reversible on discontinuation of the drug. It does not cause clinically
significant disturbances of coagulation, due to deficient synthesis of clotting factors.
Digestive tract
Upper as well as lower digestive tract symptoms are common in this type of treatment. Nausea and
vomiting can be distressing [7, 23, 32, 33] and in some cases dose-limiting [35]. Watery diarrhea has
been observed in a number of patients [15, 19, 23, 32, 33].
Blood
A dose-dependent decrease in platelets is common [20, 22, 23, 29-31, 55]. It can be very pronounced
(< 25.000/mm
3) and dose-limiting [20, 22]. However, to our knowledge, petechiae and overt bleeding
have not been reported.
A decrease in hemoglobin has also been reported, but its cause remains unclear [29]. Hemodynamic
instability will often necessitate infusion of large quantities of fluids, which in turn will aggravate any
existing low hemoglobin level.Chapter I
16
Initially, granulocytes tend to decline in numbers in the peripheral blood, probably because of
sequestration. After the infusion of r-TNF-a has been discontinued, a significant increase in numbers is
observed [9-10, 15, 18, 22, 23, 28, 31, 39, 55]. Monocytes and lymphocytes also decrease
dramatically in number in the early phase but their recovery seems to be less quick [9].
It has been shown by various authors that TNF-a has a procoagulant effect on the hemostatic
mechanism in humans through expression of tissue factor and downregulation of thrombomodulin [68-
70]. Signs of activated coagulation have been confirmed in a few clinical series [35, 39, 55, 71], but
prolonged clotting parameters are rare [48, 55]. A normal clotting profile seems to be most common
[17, 22, 23, 31-33]. Fibrinolysis is inhibited by a large increase of plasma activator inhibitor type 1
(PAI-1) and a decrease of tissue plasminogen activator (t-PA) [72, 73]. Inhibition of fibrinolysis has
been shown in healthy subjects treated with r-TNF-a [72], in patients treated with intravenous r-TNF-
a [73], and in patients treated with isolated limb perfusion with r-TNF-a and melphalan [74].
Nervous system
Neurological sequelae of treatment with r-TNF-a have been mentioned by a number of authors.
Confusion and hallucinations can be severe but seem to be quickly reversible after discontinuation of
the drug [23, 31, 33, 37]. Transient aphasia and diplopia have also been described [22, 30, 32, 33].
Three cases of blindness have been reported, one cortical [7], and two as a consequence of a retinal
vein thrombosis [14]. Seizures have been reported in one series [31].
Miscellaneous
Wasting, considered to be due to prolonged administration of r-TNF-a has been described [25].
Authors who have studied the effect of r-TNF-a on lipid metabolism have reported a decrease in
high-density lipoproteins, as well as increases in triglycerides and very-low-density lipoproteins [22].
In one series, bacteremia and sepsis were considered to be causally related to treatment with r-TNF-
a [31].
To our knowledge at least six patients have died as a consequence of treatment with r-TNF-a: one
after a cardiac arrest 90 minutes after receiving the first dose of r-TNF-a [8], two following septic
episodes during a 5-day continuous infusion [31], one from pulmonary embolism [39], one from
intracranial hemorrhage [39] and one from treatment-related pulmonary edema [39].
The most relevant side effects of hyperthermic isolated limb perfusion with r-TNF-a are
summarized in Table 1.
Clinically relevant side effects of HILP with r-TNF- Clinically relevant side effects of HILP with r-TNF- a a
hypotension hypotension
respiratory failure respiratory failure
liver cell necrosis liver cell necrosis
thrombocytopenia thrombocytopenia
fever fever
rigors rigors
malaise malaise
Table 1. Side effects.
TreatmentSide effects of treatment with TNF-a
17
Some symptoms of r-TNF-a toxicity can be prevented, others can be minimized by adequate treatment
(Table 2). There is ample evidence that non-steroidal anti-inflammatory drugs can alleviate
constitutional symptoms, probably because they are partially mediated by prostaglandins. Paracetamol
[34, 35], indomethacin [28-30], ibuprofen [10] and ketoprofen [16, 30] have been used successfully for
this indication. Routine administration of one or more of these drugs should be considered in all
patients treated with r-TNF-a. Pethidine (meperidine) is possibly effective against chills and rigor [17,
30, 34, 35, 40]. Steroids are of unproven efficacy [10].
Prevention and treatment of r-TNF-a toxicity Prevention and treatment of r-TNF-a toxicity
prevention prevention invasive monitoring invasive monitoring
volume loading volume loading
leakage monitoring leakage monitoring
low perfusion flow rates low perfusion flow rates
extensive washout extensive washout
treatment treatment invasive monitoring invasive monitoring
volume resuscitation volume resuscitation
dopamine dopamine
norepinephrine norepinephrine
positive pressure ventilation positive pressure ventilation
Table 2. Prevention and treatment of toxicity
Adequate fluid resuscitation is mandatory to prevent r-TNF-a induced hypotension as much as
possible. Patients on chronic diuretic therapy are at special risk for this complication. Volume loading
with 500-1000 ml of saline is recommended if invasive measurement of filling pressures is not feasible.
In the case of isolated limb perfusion with r-TNF-a meticulous surgical technique can limit leakage
to the systemic circulation to a minimum. Low perfusate flow rates (up to 500 ml/min for a lower limb
and up to 300 ml/min for an upper limb) have been reported to reduce systemic leakage and attenuate
side effects, probably by reducing vascular pressures in the isolated limb [55]. A thorough washout
procedure at the end of perfusion with approximately 6-10 liters of washout fluid, may also contribute
to a reduction of leakage and systemic side effects [47].
Leakage during the procedure should be monitored continuously with a radioactive marker, viz. I
131-
albumin, as described previously [75]. In this way unacceptably large leaks can be discovered early
and corrected before extensive damage is done.
Management in theatre can be facilitated by inserting a Swan-Ganz catheter after induction of
anesthesia. Most patients will require extensive fluid administration to maintain adequate filling
pressures. Since the main circulatory problem is excessive vasodilation, the majority will also require
vasopressors. In our institution all patients who have undergone isolated limb perfusion with r-TNF-a
are routinely admitted to the ICU. However, if the patient has been hemodynamically stable during
perfusion and leakage is minimal (£ 1%), the chances to develop severe toxicity are low [54] and
postoperative treatment in a 24-hour recovery facility can be considered.
Patients with a substantial leak should definitely be managed in the ICU. In our experience
hypotension and respiratory failure due to pulmonary edema are the only side-effects demanding
immediate attention. As was pointed out above, other side effects are common, but they are usually
selflimiting, do not need treatment and will not delay the patients discharge from the ICU. HypotensionChapter I
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is treated with colloids and cristalloids to maintain filling pressures. A pulmonary artery wedge
pressure of 12 mm Hg should be adequate. If hypotension persists, and it usually will, dopamine or
norepinephrine is added to maintain perfusion pressures. Norepinephrine has the advantage of not
being a positive chronotrope, as opposed to dopamine, and is a more potent vasopressor. Since most
patients will be in sinustachycardia anyway this would favor the use of norepinephrine. In view of the
hemodynamic profile of most of these patients, with a high cardiac output and low systemic vascular
resistance, norepinephrine is probably the drug of choice. If blood pressure can be maintained renal
failure is quite rare. In our own series of 64 patients only one needed continuous veno-venous
hemofiltration because of renal failure. In this patient we were unsuccessful in our attempts to maintain
adequate blood pressures.
Care should be taken that infusion of fluids does not aggravate non-cardiogenic pulmonary edema,
which in a subclinical form is present in the majority of patients [48]. If this can be avoided most
patients can be extubated within 24 hours after the perfusion procedure. Of the 64 patients treated in
our institution the median duration of post-operative ventilation was between 24 and 48 hours; only 2
patients needed mechanical ventilation for longer than 48 hours. As soon as the patient has become
hemodynamically stable, a diuretic can be useful to excrete the surplus of fluids that had to be
administered in the acute stages of the sepsis syndrome. This will usually improve oxygenation by
reducing extravascular lung water. Once symptoms in the acute phase have resolved, the patients can
be safely sent to a general ward for further care; delayed toxicity is not a feature of treatment with r-
TNF-a.
It would appear that a sepsis syndrome, that occurs as side effect of a medical intervention, is easier
to treat than sepsis from an infectious source. In the treatment of naturally occurring septic shock,
many attempts to stop the relentless propagation of the cascade of inflammatory mediators with
blocking agents have been unsuccessful, simply because they could not be given early enough in the
process. Obviously, timing of interventions could be much more favorable in iatrogenically-induced
sepsis. The set-up of isolated limb perfusion with r-TNF-a would seem ideally suited for prophylactic
treatment with a monoclonal antibody against TNF-a. Continuous systemic infusion of such an
antibody during perfusion could theoretically neutralize all r-TNF-a that would leak from the perfusion
circuit to the general circulation. If production of IL-1 could be shown to substantially increase the
toxicity of r-TNF-a, continuous systemic infusion of an IL-1 receptor antagonist could also be of
benefit. In theory, such an approach could prevent virtually all side effects of perfusion with r-TNF-a.
However, before such treatment can be attempted, it is of crucial importance to make certain that the
anti-tumor effect of r-TNF-a is in no way abrogated by anti-TNF-a antibodies, delivered systemically.
A different approach is the development of mutant TNF's, with, ideally, anti-tumor activity similar to
native TNF but reduced toxicity [76].
Finally, if nitric oxide does play a role in TNF-a induced hypotension in this setting, prophylactic
treatment with competitive inhibitors of nitric oxide formation from L-arginine, like N
G-monomethyl-L-
arginine, could block nitric oxide production and subsequently prevent excessive vasodilation. In
naturally occurring septic shock this approach has had limited success [77], but, again, it could be
more successful in a situation that permits early administration and timely discontinuation of the drug.
Concluding remarksSide effects of treatment with TNF-a
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TNF-a has a remarkable capacity to kill tumor cells in vitro, while largely sparing normal cells. Apart
from direct cytotoxic/cytostatic effects, multiple indirect processes induced by TNF-a as a "biological
response modifier", are possibly involved in regression of in vivo tumor. These include potent
immunomodulatory effects of TNF-a, in recruiting and activating immune cells, augmenting the
expression of cell surface molecules, and inducing the production of intermediate cytokines. These
characteristics make TNF potentially useful as an anti-cancer drug in vivo. Early clinical trials with
recombinant human TNF have been disappointing: at best a small clinical response has been obtained
at the cost of serious toxicity. Recently, encouraging results have been reported in patients with
irresectable extremity sarcomas and melanomas with a combination of high dose r-TNF-a, IFN-g and
an alkylating drug, administered into a system of hyperthermic isolated regional perfusion [45, 46].
Due to leakage of r-TNF-a from the perfusion system to the general circulation, this type of treatment
is also complicated by considerable clinical toxicity, mainly hypotension and respiratory failure.
However, as we and others have shown, modern intensive care is able to cope with this, providing there
is sufficient knowledge of the clinical syndrome of TNF toxicity. Our experience with this technique so
far has led us to believe that even higher doses can be tolerated by the fully monitored, sedated and
ventilated patient. In our series, serum concentrations of TNF-a with isolated limb perfusion are higher
than the levels that have been documented with the intravenous administration of 300 mg/m
2 r-TNF-a,
the dose traditionally considered to be maximal. The majority of our patients recovered within 24 hours
and could leave the ICU on the day following perfusion. Accordingly we believe that there may be a
place for new trials with intravenously administered r-TNF-a in dosages exceeding what has been
considered the maximum tolerable dose for bolus iv. administration.
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Summary
This chapter describes the post-operative course of 25 consecutive patients, who underwent
hyperthermic isolated limb perfusion with recombinant tumor necrosis factor a (r-TNF-a) and
melphalan, following pretreatment with recombinant interferon gamma (r-IFN-g), as treatment for
recurrent melanoma, primary nonresectable soft tissue tumors, planocellular carcinoma or metastatic
carcinoma. It is a retrospective, descriptive study, relating systemic TNF-a levels with indices of
disease severity.
All patients developed features of sepsis syndrome and required intensive care treatment. Most patients
recovered quickly with a median ICU stay of 2 days (range 1-25). Maximum systemic TNF-a levels
ranged from 2284 to 83000 ng/L (median 25409 ng/L) and returned to baseline values within 8 hours.
Despite these high levels of TNF-a no patient died in the ICU, although the patient with the highest
TNF-a level developed multiple organ failure and required continuous venovenous hemofiltration for
16 days.
Linear regression analysis showed a positive correlation between maximum TNF-a levels and systemic
vascular resistance (p<0.01), cardiac index (p<0.02), lung injury score (p<0.02), prothrombin time
(p<0.02) and activated partial thromboplastin time (p<0.05). It is concluded that hyperthermic isolated
limb perfusion with r-TNF-a leads to high systemic levels of TNF-a, probably due to leakage of r-
TNF-a from the perfusion circuit, mainly through collateral bloodflow. A sepsis like syndrome is seen
in all patients. Despite high levels of systemic TNF-a, this sepsis syndrome is short-lived and recovery
is rapid and complete in most patients.Sepsis syndrome in isolated limb perfusion with TNF-a
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Introduction
The cytokine TNF-a, originally defined by its antitumor activity in vivo, is now recognized to play a
key role as a polypeptide mediator in the pathogenesis of septic shock [1-7]. TNF-a has been shown to
cause myocardial depression, vasodilation, and diffuse lung injury in animal studies [8-10]. Levels of
TNF-a in the serum of septic patients show a positive correlation with the severity of illness and
mortality [11-14]. Cardiovascular, and fibrinolytic responses to the administration of endotoxin and
TNF-a have also been described in volunteer studies, although the severity of symptoms has limited
the dose used [15-18].
With hyperthermic isolated limb perfusion a very high dose of a cytostatic agent can be
administered locally in a limb while minimizing systemic toxicity. A combination of r-TNF-a, r-IFN-g
and melphalan was used in 25 patients with, mostly, primary nonresectable soft tissue tumors and
melanomas stage III A/AB of the limb, as an alternative to amputation. This triple combination with
hyperthermia was chosen because of the reported synergistic antitumor effect of r-TNF-a with r-IFN-
g, hyperthermia, and alkylating agents [19]. We have studied the clinical course of these patients and
its relationship to leakage of r-TNF-a to the systemic circulation during perfusion.
Subjects and methods
Subjects
Between January 1991 and June 1993, 25 patients received hyperthermic isolated limb perfusion at the
Division of Surgical Oncology of the Groningen University Hospital, after approval of the Medical
Ethics Committee and informed written consent had been obtained. Tumor histology is summarized in
Table 1.
TUMOR HISTOLOGY TUMOR HISTOLOGY NUMBER OF PATIENTS NUMBER OF PATIENTS
Malignant Melanoma Malignant Melanoma 7 7
Liposarcoma Liposarcoma 4 4
Malignant Fibrous Histiocytoma Malignant Fibrous Histiocytoma 3 3
Epithelioid Sarcoma Epithelioid Sarcoma 3 3
Leiomyosarcoma Leiomyosarcoma 2 2
Myxoid Chondrosarcoma Myxoid Chondrosarcoma 1 1
Malignant Schwannoma Malignant Schwannoma 1 1
Neurofibrosarcoma Neurofibrosarcoma 1 1
Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma 1 1
Planocellular Carcinoma Planocellular Carcinoma 1 1
Metastatic Renal Cell Carcinoma Metastatic Renal Cell Carcinoma 1 1
Table 1 Tumor histology.Chapter II
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Four additional patients underwent hyperthermic isolated limb perfusion without pretreatment with r-
IFN-g and without the addition of r-TNF-a to the perfusate.
Anesthesia and intensive care
Anesthesia was induced with thiopental, after which the patients were paralyzed with vecuronium and
the trachea intubated. Anesthesia was maintained with midazolam, sufentanyl, nitrous oxide and
isoflurane. After induction arterial and pulmonary artery catheters were inserted. Blood pressure, ECG,
urine output, venous and pulmonary pressures, as well as pulmonary wedge pressures and blood gas
values were checked at standard intervals. All patients were admitted to the intensive care unit
following surgery. Patients received mechanical ventilation until hemodynamically stable. Fluid
resuscitation with crystalloid and colloid solutions was given to maintain pulmonary wedge pressures
above 11 mmHg and a dopamine infusion was added if systolic arterial bloodpressure fell to 90 mmHg
or decreased by > 30 mmHg from preoperative values despite adequate fluid replacement.
Isolated Limb Perfusion
For two days prior to the perfusion patients received 0.2 mg r-IFN-g subcutaneously. The perfusion
technique employed at the Groningen University Hospital is based on the technique developed by
Creech and Krementz [20]. Briefly, after ligation of all collateral vessels and heparinization of the
patient with 3.3 mg heparin/kg bodyweight (Thromboliquine, Organon BV, Oss, The Netherlands) the
axillary, iliac, femoral or popliteal vessels were dissected, cannulated and connected to the
extracorporeal circuit. The perfused limb was wrapped in a thermal blanket to reduce heat loss and
four thermistor probes were inserted subcutaneously and intramuscularly for continuous monitoring of
the temperature during perfusion. A tourniquet was applied to the proximal limb in an attempt to
minimize leakage of the perfusate into the systemic circulation through skin collaterals. Perfusion was
performed during 90 minutes under mild hyperthermic conditions (39-40
oC). The perfusate consisted
of 350 ml 5% dextran 40 in glucose 5% (Isodex, Pharmacia AB, Uppsala, Sweden), 500 ml blood (250
ml red blood cells, 250 ml plasma), 30 ml 8.4% NaHCO3 and 0.5 ml 5000 IU/ml heparin
(Thromboliquine). The perfusate was oxygenated with a bubble oxygenator and driven by a roller
pump. At the start of perfusion r-TNF-a (Boehringer, Ingelheim, Germany, 4 mg for leg perfusions
and 3 mg for arm perfusions) and 0.2 mg r-IFN-g (Boehringer, Ingelheim, Germany) were injected as a
bolus into the arterial line of the perfusion circuit. Melphalan (Burroughs Wellcome, London, England,
10 mg/L volume of an affected leg and 13 mg/L volume of an affected arm) was administered 30
minutes later. During perfusion potential leakage to the systemic circulation was monitored with I
131 -
labeled albumin [23]. After 90 minutes of perfusion, the limb was flushed with 2 L dextran 40 in
glucose 5% (Isodex) and 500 ml blood (250 ml red blood cells, 250 ml plasma), catheters were
removed, the circulation restored and the heparin antagonized with protamine chloride. A lateral
fasciotomy of the anterior compartment of the lower leg was performed in leg perfusions or a
fasciotomy of the forearm in arm perfusions to prevent a compartment syndrome.
Four additional patients underwent hyperthermic isolated limb perfusion with melphalan in exactly
the same way but without the addition of r-TNF-a to the perfusate and without pretreatment with r-
IFN-g.Sepsis syndrome in isolated limb perfusion with TNF-a
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Hemodynamic measurements
Hemodynamic variables were measured immediately after the patient had arrived in the intensive care
unit and then at hourly intervals. Measured variables included the heart rate, mean arterial pressure,
central venous pressure, mean pulmonary artery pressure, pulmonary capillary wedge pressure.
Cardiac output, cardiac index, systemic vascular resistance and pulmonary vascular resistance were
determined at two hourly intervals. Pressure transducers were set to zero at the level of the midaxillary
line. Cardiac output was measured in triplicate by the thermodilution method, with the use of a cardiac
output computer and cold saline.
Oxygen consumption, oxygen delivery, oxygen extraction ratio and alveolar arterial oxygen difference
were calculated according to standard formulas. Lung Injury Score as a measure of Adult Respiratory
Distress Syndrome was calculated from the chest roentgenogram, hypoxemia and positive end-
expiratory pressure scores as described by Murray et al [21]. The APACHE II score was calculated
for each patient on the basis of the worst results in the first 24 hours after admission to the intensive
care unit. The Simplified Sepsis Score for each patient was calculated as described by Baumgartner et
al [22].
Assay for tumor necrosis factor
TNF-a levels were determined by specific immunoradiometric assay (Medgenix Diagnostics,
Soesterberg, the Netherlands). Samples were processed according to the guidelines of the
manufacturer. Blood samples (3 ml) from an indwelling radial artery cannula were collected in EDTA
vacutainer tubes, and kept on melting ice during transport to a centrifuge. Samples were centrifuged
for 10 min at 3000 rpm at 0
0C and the separated plasma kept at -20
0C until analysis. A baseline
sample was taken for TNF-a assay after the insertion of the arterial line, then at 5, 30, 60, and 89
minutes after the start of the perfusion. Samples from the extracorporeal circuit were also taken at the
same sampling times. After restoration of circulation to the perfused limb, systemic samples were taken
at 1, 5, 10, 30 and 60 minutes after removal of arterial clamps, hourly thereafter for at least eight
hours and finally the next morning.
Statistical analysis
Data were analyzed using SPSS for MS WINDOWS (release 5.0). Results are tabulated to show
preoperative values, mean values, standard error of the mean, and range. Correlations were sought
between variables and maximum TNF-a levels. A p-value < 0.05 was considered significant.
Results
Demographic Data
Eleven male and fourteen female patients were studied (mean age 49.2 years, range 18-74 yrs). Twenty
three perfusions of the lower limb were performed (iliac vessels cannulated in 15 patients, femoral or
popliteal vessels cannulated in 8 patients). Two perfusions of the upper limb were performed.
Histology of the tumors is summarized in Table 1. All perfusions were performed without technical
complications. Leakage from the perfused limb circuit ranged from 0 to 8% (median 2%).Chapter II
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Clinical Course
All patients developed clinical sepsis syndrome with fever, rise in cardiac output, fall in systemic
vascular resistance and the need for fluid resuscitation and inotropes. Maximum temperature,
APACHE II scores, Simplified Sepsis Scores, Lung Injury scores, fluid balance, maximum dopamine
requirements in the first 24 hrs of Intensive Care Unit (ICU) stay, and length of ICU stay are
summarized in Table 2 and 3. One patient developed multiple organ failure and required continuous
venovenous hemofiltration for 16 days.
All 4 patients who received hyperthermic isolated limb perfusion with melphalan only (i.e. without
r-TNF-a) did well without invasive hemodynamic monitoring. They did not need large infusions of
fluid or continued treatment with dopamine and were not admitted to the ICU.
PARAMETER PARAMETER MEAN MEAN SEM SEM RANGE RANGE
Length of stay (days) Length of stay (days) 3* 3* 1-25 1-25
Maximum temperature (  Maximum temperature ( 
0 0C) C) 40.0 40.0 0.12 0.12 39.0-41.8 39.0-41.8
APACHE II Score APACHE II Score 15.6 15.6 0.66 0.66 11-22 11-22
Simplified Sepsis Score Simplified Sepsis Score 4.9 4.9 0.4 0.4 1-9 1-9
Fluid Balance 1ST 24HRS (L) Fluid Balance 1ST 24HRS (L) +10.15 +10.15 0.87 0.87 +2.43 - +18.93 +2.43 - +18.93
Time to Extubation (days) Time to Extubation (days) 2* 2* 0-21 0-21
SEM, standard error of the mean.
*nonparametric distributed variable, therefore mean value should be read as median and no standard error of
the mean is given.
Table 2  Clinical course data.
TNF-a levels
Systemic TNF-a levels were measured in 13 patients. Maximum TNF-a levels ranged from 2284 to
83000 ng/L (median 25409 ng/L). TNF-a levels peaked towards the end of the isolated limb perfusion
and immediately after reperfusion of the limb. Levels then rapidly declined over the next hours of
measurement (Figure 1).
TNF-a was detected in plasma up to 8 days after perfusion, but at very low levels. In the 4
patients who were treated with hyperthermic isolated limb perfusion without pretreatment with r-IFN-g
and without the addition of r-TNF-a to the perfusate, maximum postperfusion TNF-a levels ranged
form 1-53 ng/L (mean 42 ng/L, standard deviation 22 ng/L, standard error of the mean 11 ng/L).Sepsis syndrome in isolated limb perfusion with TNF-a
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Fig. 1 Median systemic TNF-a a levels (straight line and black squares) with SEM and median
TNF-a a levels and SEM in the perfusion circuit (dotted line and open circles).
Hemodynamic Variables
A full set of values for cardiac output, cardiac index, systemic vascular resistance and pulmonary
vascular resistance was available for 22 patients. Cardiovascular variables on admission to the ICU
are summarized in Table 3.
PARAMETER PARAMETER BEFORE BEFORE MAXIMUM MAXIMUM SEM SEM RANGE RANGE
Cardiac Index (L/min/m Cardiac Index (L/min/m
2 2) ) 3.06 3.06 6.3 6.3 0.4 0.4 3.6-9.9 3.6-9.9
SVR dyne.sec/cm SVR dyne.sec/cm
5 5 1055 1055 537 537 27 27 317-757 317-757
PVR dyne.sec/cm PVR dyne.sec/cm
5 5 n.a. n.a. 79 79 6 6 21-133 21-133
DO DO 2 2 (ml/min)  (ml/min) n.a. n.a. 759 759 49 49 420-1341 420-1341
VO VO 2  2 (ml/min) (ml/min) n.a. n.a. 183 183 25 25 73-401 73-401
Extraction ratio Extraction ratio n.a. n.a. 0.21 0.21 0.03 0.03 0.1-0.4 0.1-0.4
Max. Dopamine conc. (mg/kg/min) Max. Dopamine conc. (mg/kg/min) 0 0 5.1 5.1 0.6 0.6 0-10.2 0-10.2
AaGradient AaGradient n.a. n.a. 20.6 20.6 2.0 2.0 10-59.3 10-59.3
Lung Injury Score Lung Injury Score 0 0 0.88 0.88 0.2 0.2 0-3 0-3
Thrombocytes (x10 Thrombocytes (x10
9 9/L)(normal 150-400) /L)(normal 150-400) 286 286 108 108 11 11 22-228 22-228
Fibrinogen (g/L)(normal 1.7-3.5) Fibrinogen (g/L)(normal 1.7-3.5) 4.3 4.3 2.2 2.2 0.3 0.3 0.9-5.2 0.9-5.2
PT (sec)(normal 11-16) PT (sec)(normal 11-16) 13.7 13.7 22.7 22.7 1.4 1.4 14.9-34.5 14.9-34.5
APTT (sec)(normal 26-36) APTT (sec)(normal 26-36) 35.6 35.6 46.2 46.2 3.1 3.1 25.5-64.9 25.5-64.9
ATIII (%)(normal 80-120) ATIII (%)(normal 80-120) 85 85 47.6 47.6 5.0 5.0 27-77 27-77
SEM, standard error of the mean; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance;
DO2, oxygen delivery; VO2, oxygen consumption; Max, maximum; AaGradient, alveolair arterial oxygen
difference; PT, prothrombin time; APTT, activated partial thromboplastin time; ATIII, antithrombin III.
Table 3 Hemodynamic, respiratory and coagulation variables.
Linear regression analysis showed significant correlations between maximum TNF-a levels and
systemic vascular resistance (p < 0.02, r=0.70), cardiac index (p < 0.02, r=0.72), volume of fluidChapter II
32
infused in the operating room (p < 0.02, r=0.69) and in the ICU (p<0.02, r=0.80) and maximum
infusion rate of dopamine (p < 0.02, r=0.69).
Respiratory System
Twenty patients remained intubated for less than 24 hrs, 3 for 24-48 hrs and 2 patients required
prolonged ventilatory support (14 and 21 days). Respiratory variables are summarized in Table 3.
There was a significant correlation between maximum TNF-a level and the Lung Injury Score (p <
0.02, r=0.64).
Renal Function
One patient developed multiple organ failure and required continuous venovenous hemodialysis for 16
days. The remaining 24 patients showed no significant change in creatinine clearance from
preoperative values. The patient who developed multiple organ failure had the highest top level of
TNF-a recorded in this study: 83.000 ng/L.
Coagulation Parameters
Coagulation parameters are summarized in Table 3. Values for thrombocyte count were available for
24 patients, fibrinogen levels for 16 patients, prothrombin time and activated partial thromboplastin
times for 15 patients, and antithrombin III levels in 14 patients. There were significant correlations
between maximum TNF-a level and prothrombin time (p < 0.02, r=0.79) and activated partial
thromboplastin time (p < 0.05, r=0.72) but not with fibrinogen and antithrombin III levels.
Discussion
Isolated limb perfusion with r-TNF-a, melphalan and r-IFN-g produced a severe but short-lived
systemic reaction characterized by high fever, high cardiac output, low peripheral resistance, activated
clotting and an increased A-a gradient for oxygen. All patients required either fluid resuscitation or
dopamine infusion or both to maintain adequate bloodpressure. The clinical picture resembled septic
shock and adult respiratory distress syndrome, lasting for about 24 hours. Since, in 4 other patients,
perfusion with only melphalan (without r-TNF-a and r-IFN-g) did not trigger a rise in systemic TNF-a
levels, and extremely high levels of TNF-a were measured in the systemic circulation of the patients
described here, both during and shortly after perfusion, leakage of r-TNF-a from the perfusion system
into the systemic circulation is likely to be the explanation for the sepsis-like state that was observed.
Washout of remnant r-TNF-a once the circulation was restored may have contributed to the high
systemic TNF-a levels. The observed leakage of I
131 labeled albumin from the perfusion system, which
ranged between 0 and 8% (median 2%) supports the role of TNF-a leakage as the primary cause of the
postoperative events described earlier. The extent of leakage is similar to that reported in the literature
[23]. Moreover, it is known from animal experiments, that administration of r-TNF-a leads to tissue
injury and metabolic derangements similar to those seen in septic shock [24]. In theory, systemic TNF-
a levels in these patients may also have been raised by the systemic response to extracorporeal
circulation, hyperthermia, and the presence of indwelling plastic cannulae [25 -27]. Tissue damage
induced by the combined effects of heat, melphalan and r-TNF-a was also considerable in all cases and
this in itself could have contributed to an increase in TNF-a levels and signs of systemic inflammatory
response. However, we feel that the TNF-a levels we measured were too high to be explained bySepsis syndrome in isolated limb perfusion with TNF-a
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endogenous production of this cytokine. Maximum systemic TNF-a levels (median 25409 ng/L, range
2284-83000) were several orders of magnitude higher than TNF-a levels previously reported in other
forms of shock. In a series of 79 patients with meningococcal disease and/or septicemia all patients
with TNF-a levels over 100 ng/L died [28]. In septic shock median TNF-a levels of 120 ng/L have
been reported [11]. In our patients TNF-a levels were very high initially but fell rapidly: 12 hours
postperfusion TNF-a levels had returned to baseline values. In view of their high TNF-a levels
recovery in our patients was remarkably rapid: 80% could be transferred from the ICU the day
following perfusion. How can this discrepancy between TNF-a levels and clinical course be explained?
Theoretically the measured systemic TNF-a levels could represent an inactive form of the
polypeptide. Since the preparation was tested in a bioassay by the manufacturer it is unlikely that r-
TNF-a was administered to the patients in an inactive form. It has recently been shown that TNF-a
binds to two different types of receptors, one of them 55 kilodalton in size, the other 75 kilodalton. The
extracellular portions of these receptors, TNF-a binding protein type 1 and 2 respectively, can become
separated from the cellmembrane by proteolysis, and can bind and inactivate TNF-a in the circulation.
In theory, rapid and extensive binding of r-TNF-a to these soluble receptors could therefore explain the
relatively mild clinical course in our patient group. In our study only total TNF-a was measured.
Because of these limitations the question whether the high TNF-a levels represent unbound, active
TNF-a cannot be answered. Future studies should determine both unbound TNF-a and TNF-a soluble
receptor complexes. TNF-a in our series was not cleared fast; the mean half-life of 80 minutes in our
patients is considerably longer than the 10 - 15 minutes reported in the literature. It has been suggested
that patients with cancer are chronically exposed to increased levels of endogenous TNF-a and so may
have increased tolerance to the effects of TNF-a [29]. The patients in this study received r-IFN-g
subcutaneously for 2 days preoperatively to sensitize them to the effects of TNF-a. In animals this is
highly effective [30]. It is not unreasonable to assume that any downregulation of receptors in our
patients was probably negated by the effects of r-IFN-g pretreatment. Moreover, baseline values of
plasma TNF-a were several orders of magnitude lower than maximum TNF-a levels so any pre-
existing tolerance probably had insignificant effects on the subsequent clinical course. Pinsky and
coworkers have shown that the persistence of TNF-a and IL-6 levels rather than peak levels of
cytokines predicts a poor outcome in patients with septic shock [31]. Accordingly, it is possible that the
rapid decline in TNF-a levels and the lack of a repetitive stimulus for TNF-a release was the reason
that our patients recovered so quickly with no deaths in this series.
Finally it should be borne in mind that much of the injury induced by TNF-a results from local
production of the protein and its subsequent action at short range. Systemic levels of this cytokine only
weakly reflect what is going on at the local level. Low levels in the circulation do not exclude high
levels of TNF-a in the tissues and, inversely, high systemic levels do not necessarily reflect high
concentrations in the tissues of the patient.
As far as management of these patients in the ICU is concerned, hypotension was the key problem
and the presence of a Swan-Ganz catheter proved to be very valuable in its treatment. Colloids and
cristalloids were infused to a pulmonary wedge pressure of 12 mmHg. However, large infusions of
volume (mean of 10 L within the first 24 h) did not correct the hypotension in the majority of patients.
Accordingly 24 out of 25 patients were treated with intermediate dose dopamine infusions (mean 5
mg/kg/min). The patient with the highest TNF-a level also needed norepinephrine to maintain adequate
bloodpressure but this could not prevent the development of renal failure. Dopamine could usually be
stopped the day following admission to the ICU and the Swan-Ganz catheter was removed a few hoursChapter II
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later. All patients but one retained good renal function. A large spontaneous diuresis followed the
resolve of the sepsis syndrome on day 2. Patients were ventilated in a pressure support mode as soon as
their ventilatory drive was restored following anesthesia. Signs of Adult Respiratory Distress
Syndrome were usually discrete and only two patients needed high levels of positive end-expiratory
pressure or inspiratory oxygen concentration to maintain adequate saturation. These two patients
required mechanical ventilation for almost three weeks. Successful extubation was performed in 21 out
of 25 patients within 24 hours. Clinically relevant coagulopathy was not observed in any patient.
There is little doubt that patients undergoing isolated limb perfusion with r-TNF-a will benefit from
postoperative care in an ICU. Data derived from a Swan-Ganz pulmonary artery catheter are helpful to
direct fluid administration and treatment with inotropes. Preferably a pulmonary artery catheter is
introduced before the perfusion is started.
In conclusion this study shows that isolated limb perfusion with r-TNF-a leads to very high
systemic TNF-a levels and transient serious signs of sepsis, pulmonary dysfunction and activated
clotting, probably due to leakage of r-TNF-a from the perfusate. Despite high systemic TNF-a levels
recovery in most cases is rapid and complete.
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Summary
Several investigators have reported that interferon gamma can alter tumor necrosis factor alpha induced
effects in vitro. We assessed in vivo effects of recombinant interferon gamma (r-IFN-g) on recombinant
tumor necrosis factor alpha (r-TNF-a) induced activation of systemic blood coagulation in a non-randomized
study in 20 consecutive cancer patients. Eight patients were treated with r-IFN-g prior to and during
hyperthermic isolated limb perfusion with r-TNF-a and melphalan (IFN-g group). They were compared with
twelve patients who did not additionally receive r-IFN-g (non-IFN-g group).
Before start of perfusion, higher levels of TNF-a, prothrombin fragment 1 and 2 (F1+2)and thrombin-
antithrombin-complexes (TAT) were found in the IFN-g group. Fibrinogen and antithrombin III (ATIII)
levels tended to be lower in this group. High TNF-a levels, due to leakage during perfusion, were associated
with activation of coagulation in all patients, that became obvious after the end of perfusion, when heparin
treatment had been antagonized. Activation, measured by increased F1+2 and TAT levels, was significantly
stronger in the IFN-g group. Monocytic tissue factor (TF) remained low, possibly due to shedding of TF
positive vesicles and/or sequestration of TF positive activated monocytes against the vessel wall. In both
groups F1+2 and TAT levels declined 24 hours after the perfusion, whereas monocytic TF increased to levels
that were higher in the IFN-g group.
In conclusion, our data confirm a strong activation of coagulation induced by r-TNF-a in cancer patients.
They suggest that r-IFN-g may lead to a slight activation of coagulation and augments TNF-a induced
procoagulant activity. These effects may be due to r-IFN-g induced sustained monocytic TF activity.Augmented procoagulant activity in isolated limb perfusion with TNF-aand interferon-g
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Introduction
Tumor necrosis factor alpha (TNF-a), an inflammatory mediator, has been demonstrated to play an
important role in several pathological and experimental conditions [1-5]. It also has been associated with
disturbances of the hemostatic balance, particularly changes of coagulation and fibrinolysis [6,7].
Administration of recombinant TNF-a (r-TNF-a) to both cancer patients [6] and healthy volunteers [7]
resulted in activation of coagulation. Since the intrinsic pathway of coagulation was not activated [7], it
seems likely that TNF-a acts by activation of the extrinsic route. Tissue factor (TF) is assumed to be the
main in vivo initiator of this pathway [8-10]. Under normal conditions TF is not found on cells in direct
contact with blood [11,12]. However, TF expression can be induced in vitro by TNF-a both in monocytes
[13,14] and endothelial cells [15,16].
In vivo, several cytokines are present concomitantly or consecutively so that they may contribute to
amplification or inhibition of their respective activities. It has been demonstrated that one of these cytokines,
interferon gamma (IFN-g), augments macrophage procoagulant activity induced by TNF-a in vitro [17].
Reports on in vivo and in vitro induction of TF expression by IFN-g itself are inconsistent [18-21]. Recent in
vitro findings suggest that adhesion of lymphocytes to IFN-g stimulated endothelium results in TNF-a
production and subsequent induction of endothelial TF [22]. In the present study, we assessed the effects on
blood coagulation of recombinant IFN-g (r-IFN-g), administered to cancer patients in addition to r-TNF-a
and melphalan.
Materials and Methods
Patients
Twenty consecutive patients with either advanced melanomas or nonresectable soft tissue tumors of a limb
were treated by hyperthermic isolated limb perfusion [23]. Two different therapeutic regimes were applied
(Fig. 1).
Subcutaneous Perfusion circuit
  10-13 mg/L Melphalan
0.2 mg IFN- g 0.2 mg IFN- g 3-4 mg TNF-a
Œ Œ 0.2 mg IFN- g
0 min 30 min 90 min
Day -2 Day -1 Day of perfusion                   time
Fig. 1 Treatment scheme. Eight patients received IFN-g g, TNF-a a and melphalan (IFN-g g group), 12
patients only TNF-a a and melphalan (non IFN-g g group).Chapter III
40
The first eight patients received a combination of r-IFN-g, r-TNF-a and melphalan (IFN-g group). The
remaining twelve patients received only r-TNF-a and melphalan (non-IFN-g group). Patients with abnormal
hepatic and/or renal function were excluded. The study protocol was approved by the medical ethical
committee of our hospital.
Hyperthermic isolated limb perfusion
The perfusion technique employed is based on a technique developed by Creech and Krementz [24]. Briefly,
after ligation of all collateral vessels and heparinization of the patient with 3,3 mg heparin/kg body weight iv,
either the axillary, iliac, femoral or popliteal vessels were dissected, cannulated and connected to an
extracorporeal circuit. A tourniquet was applied to the proximal limb in an attempt to minimize leakage of
the perfusate into the systemic circulation. Perfusion was performed during 90 minutes under mild
hyperthermic conditions (39-40°C). The perfusate consisted of 350 ml 5% dextran 40 in glucose 5%, 500 ml
blood products (250 ml red blood cells, 250 ml plasma), 30 ml 8.4% NaHCO3 and 0.5 ml 5000 IU/ml
heparin (Thromboliquine
R). At the start of the perfusion r-TNF-a (Boehringer Ingelheim, Ingelheim,
Germany; 4 mg for leg perfusions and 3 mg for arm perfusions) was injected as a bolus into the arterial line
of the perfusion circuit. Melphalan (Burroughs Wellcome, London, England, 10 mg/L volume of an affected
leg and 13 mg/L volume of an affected arm) was administered 30 minutes later. Treatment with r-IFN-g
consisted of a daily subcutaneous injection with 0.2 mg r-IFN-g on the two days preceding perfusion and a
bolus injection of 0.2 mg r-IFN-g into the perfusion circuit. After 90 minutes of perfusion, the limb was
flushed with 2 L dextran 40 in glucose 5% and 500 ml blood products (250 ml red blood cells, 250 ml
plasma), catheters were removed, the circulation restored and heparin antagonized with protamine chloride.
A lateral fasciotomy of the anterior compartment of the lower leg was performed in leg perfusions or a
fasciotomy of the forearm in arm perfusions to prevent a compartment syndrome.
Sample collection
Blood samples were collected from an indwelling radial artery cannula and anticoagulated with either EDTA
(TNF-a measurements) or 1/10th volume of 0.109 mol/L trisodium citrate, pH 6.0 (all other measurements).
Samples were taken before start of the perfusion, 5 minutes after starting perfusion, 1 min before ending
perfusion, and 5 min, and 2 and 24 hours after restoration of the circulation. Collected blood samples were
kept on melting ice during transport to the laboratory. Plasmas were prepared by centrifugation at 2000 x g
and subsequently at 14,000 x g to remove residual platelets and stored at -80 °C until analysis. Mononuclear
cell (MNC) suspensions were obtained by density-gradient centrifugation on Ficoll-Hypaque.
Assays
TNF-a concentrations were measured using a specific immunoradiometric assay (Medgenix Diagnostics,
Soesterberg, The Netherlands). Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin III complex
(TAT) levels were measured using enzyme linked immunosorbent assays (ELISA) provided by Baxter,
Miami, Florida (USA) and Behringwerke, Marburg, (Germany), respectively. Normal values for F1+2 ranged
(geometric mean ± 2SD) from 0.08 to 0.51 nmol/L and for TAT from 1.0 to 4.1 mg/L. Levels of
antithrombin III (ATIII) and fibrinogen (Fg) were measured by standard laboratory methods. Normal values
ranged from 74 to 113% and 1.7 to 3.5 g/L, respectively. Monocytic procoagulant activity was measured in
cell lysates, prepared by resuspending the MNCs in assay buffer (10 mmol/L HEPES, 137 mmol/L NaCL, 4
mmol/L KCL, 11 mmol/L D-glucose, 5 mg/ml of ovalbumin and 2.5 mmol/L CaCL2, pH 7.45) and
subsequent exposure to three freeze-thaw cycles (-80°C/37°C). TF activity was determined by a two-stage
amidolytic assay [25]. Since TF activity is exclusively generated by monocytes in this system, monocytesAugmented procoagulant activity in isolated limb perfusion with TNF-aand interferon-g
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were not purified from the mixed mononuclear cell population before estimating monocytic procoagulant
activity and the data were expressed as TF activity/monocyte. The estimated numbers of monocytes were
calculated from its proportion in the MNC fraction of whole blood multiplied by the number of isolated
MNCs. Normal values for TF, estimated in a group of 12 healthy individuals, comparable in age and sex
with the treatment groups, ranged from 0 to 227 fmol Xa/min/10
6 cells.
Statistical analysis.
TF, F1+2 and TAT data were LOGe-transformed, because they were skewed. Differences between the
medians or means of both groups were analyzed using the program CIA (confidence interval analysis) [26].
When the 95% or 99% confidence intervals for the mean levels at separate time points did not overlap the
normal range, the values were considered significantly different from normal. When the 95% or 99%
confidence intervals for the difference between medians (TNF-a measurements) or means (all other
parameters) of both groups did not contain zero, the difference was considered statistically significant. The
course of monocytic TF activity was analyzed with the random coefficient model.
Results
Before perfusion, the IFN-g group as compared with the non-IFN-g group showed a higher median level of
TNF-a (25 vs 10 ng/L, p<0.01), and higher mean levels of F1+2 (0.51 vs 0.23 nmol/L, p<0.01, Fig. 2) and
TAT (12.1 vs 4.6 mg/L, p<0.01, Fig. 3).
0 1 2 3 4 5 6
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
12 24
ILP
* *
*
time (hrs)
F
 
1
 
+
 
2
 
l
e
v
e
l
s
 
(
n
m
o
l
/
L
)
Fig. 2 Geometric means of F1+2 (nmol/L) in patients who were treated by hyperthermic isolated limb
perfusion (ILP) with TNF-a a and melphalan, with (interrupted line) or without (solid line) IFN-g g.
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Fig. 3 Geometric means of TAT (mg/L) levels in patients who were treated by hyperthermic isolated
limb perfusion (ILP) with TNF-a a and melphalan, with (interrupted line) or without (solid line)
IFN-g g. * : p<0.01. #: p<0.05.
Mean levels of TF (184 vs 145 fmol Xa/min/10
6cells, Fig. 4), ATIII (63 vs 73%) and Fg (2.72 vs 3.31 g/L)
were not significantly different in both groups.
TNF-a concentrations increased during perfusion (IFN-g group, 24180 ng/L and non-IFN-g group,
18159 ng/L), followed by a decline after perfusion. At 24 hours, TNF-a concentrations remained elevated as
compared with baseline values (123 and 122 ng/L, respectively). There were no statistically significant
differences between the two groups.
F1+2 and TAT levels did not change during perfusion (Fig. 2 and 3). They increased afterwards with
maximum levels measured two hours after perfusion. The differences present at baseline were maintained
over time. At 24 hours, F1+2 levels approximated baseline values (IFN-g group, 0.54 nmol/L and non-IFN-g
group, 0.28 nmol/L; p<0.01), while TAT levels, although declined, were still elevated (21.2 vs 13.1 mg/L,
p<0.05).
AT-III and Fg levels in both groups decreased slightly during perfusion. Fg levels returned to pre-
perfusion levels at 24 hours, while ATIII levels remained lowered. There were no statistically significant
differences between the two groups (data not shown).
Although the difference in monocytic procoagulant activity between the two treatment groups was not
statistically significant at the end of the perfusion, monocytic TF activity showed a different course in both
groups, as was demonstrated by the random coefficient model (Fig. 4).Augmented procoagulant activity in isolated limb perfusion with TNF-aand interferon-g
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Fig. 4 Geometric means of monocytic TF activity (fmol Xa/min/10
6 cells) in patients who were treated
by hyperthermic isolated limb perfusion (ILP) with TNF-a a and melphalan, with (interrupted
line) or without (solid line) IFN-g g. # : p<0.05 (comparison between the two groups), ‡ : p<0.05
(compared with baseline in the IFN-g g group).
A quadratic equation resembled the course in the IFN-g group (p=0.0019), while a linear equation was found
in the non-IFN-g group (p=0.02). A significant, more than two-fold decrease of monocytic TF activity was
found in the IFN-g group during perfusion, while the levels in the non-IFN-g group did not change
significantly. Two hours after the end of perfusion, monocytic TF activity had returned to its approximate
pre-perfusion level in the IFN-g group, while TF levels in the non-IFN-g group had remained unchanged. At
24 hours, TF levels in both groups showed a clear increase to levels that were higher in the IFN-g group than
in the non-IFN-g group (560 vs 380 fmol Xa/min/10
6 cells, p<0.05).
Discussion
We studied the effects of r-IFN-g treatment on r-TNF-a induced activation of coagulation in patients with a
malignancy of a limb. Twelve of these patients, who were treated by hyperthermic isolated limb perfusion
with r-TNF-a and melphalan, were compared with 8 patients, who additionally received r-IFN-g prior to and
during perfusion (Fig. 1).
Patients who had received r-IFN-g for two days showed higher levels of TNF-a, F1+2 and TAT prior to
perfusion, as compared with controls. Levels of ATIII and fibrinogen tended to be lower. These differences
might be due to r-IFN-g induced monocytic TF activity. In vitro studies have provided conflicting data on the
potency of IFN-g to induce TF [18-21]. Nevertheless, it has been demonstrated that IFN-g increases
macrophage TNF-a production [27] and more recently, Schmid et al. showed that adhesion of lymphocytes
to IFN-g stimulated cultured endothelium resulted in TNF-a production with subsequent induction of
endothelial TF [22]. These observations are consistent with our findings, showing higher F1+2 and TAT levels
that coincided with an elevated endogenous TNF-a level in the IFN-g group. IFN-g possibly acts indirectly
on the coagulation system by increasing TNF-a activity.Chapter III
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Five minutes after start of limb perfusion, systemic TNF-a levels strongly increased in all patients.
Apparently, significant leakage of r-TNF-a occurred in spite of isolated limb perfusion. As expected,
considering that TNF-a-induced monocytic TF expression peaks after six hours [18] and a high dose of
heparin was administered, there were no signs of activation of coagulation during perfusion. Accordingly,
F1+2 and TAT levels did not change. A simultaneous decrease of ATIII and Fg was probably due to dilution
by massive fluid infusion, rather than consumption of these proteins secondary to activated coagulation.
Consistently, systemic monocytic TF activity did not change markedly during perfusion in the non-IFN-g
group. However, a statistically significant and more than two-fold decrease was observed in the IFN-g group.
Several mechanisms could account for this apparently paradoxical decrease in TF activity, including
neutralization by an inhibitor, shedding of TF containing membrane vesicles, or loss of peripheral circulating
TF positive monocytes. Increased neutralizing activity by inhibitors, like tissue factor pathway inhibitor or
ATIII, possibly potentiated by heparin [28,29], is unlikely. This would have resulted in a reduction of TF
activity to the same extent in both groups. Moreover, IFN-g has not, to our knowledge, been reported to
stimulate expression of one of these inhibitors [30]. Shedding of TF-rich vesicles has been observed from the
surface of tumor cells [31], fibroblasts [32], and monocytes [33]. Accordingly, recent findings have
demonstrated that TNF-a only causes shedding of L-selectin [34] or leukocytic activation [35,36] in the
presence of secondary stimuli. Thus, loss of monocytic TF by shedding of TF-rich vesicles induced by TNF-
a in the presence of IFN-g, might be a more valid explanation.
Alternatively, we speculate that migration of TF positive monocytes from the systemic circulation could
have contributed to the decrease in measured monocytic TF activity. The latter view is supported by reports
showing that IFN-g can promote upregulation of specific adhesion molecules for adhesion of monocytes to
endothelium [37,38]. In this study, we found, in line with previous findings [39], that MNC counts decreased
rapidly in all patients after start of the perfusion (data not shown), suggesting peripheral consumption rather
than bone marrow suppression. Because we did not purify monocytes from the mixed MNC population
before estimating monocytic procoagulant activity, we can not provide direct evidence for loss of TF positive
monocytes from the systemic circulation.
After heparin had been antagonized at the end of perfusion, a strong increase in F1+2 and TAT levels was
observed in both treatment groups, in agreement with previous reports on activation of coagulation by TNF-
a administered to cancer patients and healthy humans [6,7]. It should be noticed that actual F1+2 and TAT
levels were higher if corrected for dilution. Moreover, our data suggest that the effects of r-TNF-a on
coagulation are potentiated by r-IFN-g, as F1+2 and TAT levels remained higher in the IFN-g group.
However, monocytic TF activity showed only a limited increase in the IFN-g group, while in the non-
IFN-g group the levels even remained unchanged, despite pronounced activation of coagulation in both
treatment groups. Perhaps mechanisms like induction of endothelial TF or concentration of monocytes at
vessel wall sites thus supporting TF-independent, factor VIIa-mediated activation of factor X [40] might
have been the cause of this apparent discrepancy. Alternatively, activation of coagulation might have been
due to TF, expressed on shed vesicles and/or on the surface of adherent, activated monocytes. Monocytic TF
activity, as measured in the systemic circulation under our experimental conditions, probably depends on the
balance between induced expression of monocytic TF and loss of it through shedding of TF positive vesicles
and/or sequestration of TF positive activated monocytes. Because we measured only a limited increase in
monocytic TF activity, despite pronounced activation of coagulation, we hypothesize that most of the
monocytic TF was shed and/or most of the TF positive monocytes participated in vessel wall associated
coagulation.
Consistent with the latter hypothesis, we found 24 hours after perfusion in both treatment groups low
F1+2 and TAT levels concomitantly with increased monocytic TF, possibly residual from maximal inductionAugmented procoagulant activity in isolated limb perfusion with TNF-aand interferon-g
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by TNF-a earlier after perfusion, considering that TNF-a-induced monocytic TF expression peaks after six
hours [18]. The higher level of monocytic TF in the IFN-g group at that time might be attributed to a late
effect of r-IFN-g, as IFN-g induced TF activity is maximal at 24 hours [18].
Because of the non-randomized design of this study and the small number of patients, the observed
differences between the two groups might be attributed to selection bias. However, consecutive patients were
enrolled and there were no differences in clinical baseline characteristics between the two groups. Another
more important limitation is the absence of measurements two days before perfusion, to assure comparability
of the groups with regard to the reported parameters prior to r-IFN-g treatment.
In conclusion, the results of this study in cancer patients confirm previous reports on a strong activation
of coagulation induced by r-TNF-a administration. Furthermore, our data suggest that r-IFN-g may lead to a
slight activation of coagulation, due to increased endogenous production of TNF-a, and augments TNF-a
induced procoagulant activity by sustained induction of monocytic TF.
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Summary
This study was undertaken to determine the effects on systemic fibrinolysis of hyperthermic isolated
limb perfusion with recombinant tumor necrosis factor alpha (r-TNF-a) and melphalan, with or
without pretreatment with recombinant interferon gamma (r-IFN-g). Twenty patients were treated with
r-TNF-a and melphalan; four patients, treated with melphalan only, served as controls. Of the twenty
patients treated with both r-TNF-a and melphalan, eight received r-IFN-g for two days before the
perfusion and as a bolus into the perfusion circuit. A significant leak of r-TNF-a from the perfusion
circuit to the systemic circulation was observed in all r-TNF-a treated patients (mean maximum TNF-
a 87227 ng/liter versus 31 ng/liter in controls, p<0.002). In these patients, but not in controls, there
was an almost instantaneous rise in systemic tissue plasminogen activator (t-PA) activity (from 0.26
IU/ml to 5.28 IU/ml in 90 min), causing activation of fibrinolysis. After a delay of 90 minutes,
plasminogen activator inhibitor-1 (PAI-1) antigen rose to high levels in the r-TNF-a treated group
(mean maximum PAI-1 1652 ng/ml versus 211 ng/ml in controls, p<0.02), associated with a sharp
decrease of tPA-activity and a slower decrease of plasminogen-antiplasminogen complexes (from 5.28
IU/ml to 0.02 IU/ml in 2 h, and from 1573 mg/L to 347 mg/L in 22 h respectively). No additional effect
of IFN-g pretreatment on fibrinolysis could be demonstrated. These results suggest that in isolated limb
perfusion with r-TNF-a and melphalan an initial activation of systemic fibrinolysis, induced by
leakage of r-TNF-a from the perfusion circuit, is set off by a subsequent inhibition of the fibrinolytic
system by PAI-1. This large increase in PAI-1 could place the patient at risk for deposition of
microthrombi in the systemic circulation.Effects of isolated limb perfusion with TNF-a on sytemic fibrinolysis
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Introduction
Isolated limb perfusion with cytotoxic drugs is used in patients with nonresectable soft tissue tumors
and locally advanced melanomas of a limb, as an alternative to amputation [1,2]. It allows the
administration of high doses of cytostatic agents locally while minimizing systemic toxicity.
Traditionally an alkylating agent like melphalan has been added to a mildly hyperthermic perfusate.
Recently melphalan has been combined with recombinant tumor necrosis factor alpha (r-TNF-a) in an
attempt to maximize the anti-tumor effect of the perfusion [3-5]. Some of these patients have been pre-
treated with recombinant interferon gamma (r-IFN-g) to enhance the sensitivity of the tumor to r-TNF-
a [3-5]. Human r-IFN-g increases the number of TNF-receptors on human tumor cells [6, 7].
Additionally, r-TNF-a and r-IFN-g show synergy in antitumor effects on human tumor cells and on
human melanoma xenografts in nude mice [8-10].
It has been recognized by us, as well as by others, that isolated limb perfusion with r-TNF-a
induces a sepsis like state in all patients, characterized by fever, tachycardia and a low blood pressure
due to systemic vasodilation [11, 12]. Vigorous fluid resuscitation and vasopressor therapy are usually
required to maintain adequate tissue perfusion. The sepsis response can be quite severe but is
remarkably short-lived: most patients can be discharged from the intensive care unit on the day after
perfusion. The occurrence of this syndrome is explained by leakage of r-TNF-a from the perfused limb
into the systemic circulation; very high levels of TNF-a have been documented in peripheral blood of
these patients during and directly after perfusion. Leakage has been confirmed by adding radiolabeled
albumin to the perfusate, which can be traced to the systemic circulation during the procedure [13].
Lower perfusate flow rates have been reported to reduce systemic leakage and attenuate side effects,
probably by reducing vascular pressures in the isolated limb [14]. A thorough washout procedure at
the end of perfusion may also contribute to a reduction of leakage and systemic side effects [12].
In vitro and in vivo experiments have shown the effects of TNF-a on blood coagulation and
fibrinolysis to be profound, although the mechanism is still incompletely understood [15]. Because
patients treated with isolated limb perfusion with r-TNF-a show high systemic TNF-a levels, it was
hypothesized that blood coagulation and fibrinolysis in these patients may be profoundly disturbed,
especially during and directly after perfusion. In theory, either a bleeding diathesis or, conversely, a
prothrombotic state could well occur as a consequence of the treatment and expose the patient to an
additional risk.
The aim of this study was to investigate the effects of isolated limb perfusion with r-TNF-a and
melphalan on systemic fibrinolysis. Because part of the study population was additionally treated with
r-IFN-g before and during perfusion the added effects of r-IFN-g on fibrinolysis were also studied.Chapter IV
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Patients and Methods
Outline of Experiments.
Patients treated with r-TNF-a (with or without additional treatment with r-IFN-g) were compared with
control patients who received melphalan only. Subsequently, patients additionally treated with r-IFN-g
were compared with patients who had no such additional treatment, in order to evaluate the effects of r-
IFN-g in addition to r-TNF-a.
Blood samples (before, during and after perfusion) were taken at regular intervals to determine TNF-a
levels and parameters of fibrinolysis. Activation of the fibrinolytic system was monitored by measuring
t-PA antigen and activity. Inhibition of the fibrinolytic system was measured by determining levels of
PAI-1. The balance between activation and inhibition was assessed by determining FbDP (fibrin
degradation products) and PAP (plasminogen - anti-plasminogen complexes).
Subjects.
Between April 1993 and June 1994, 24 patients received hyperthermic isolated limb perfusion at the
division of surgical oncology of the Groningen University Hospital after approval of the medical ethical
committee and informed consent had been obtained. Of these 24 patients, 12 received melphalan and r-
TNF-a without additional treatment with r-IFN-g, 8 received melphalan and r-TNF-a with additional
r-IFN-g treatment and the remaining 4 were treated with melphalan only.
Anesthesia and Intensive Care.
Anesthesia was induced with thiopental, after which the patients were paralyzed with vecuronium and
the trachea was intubated. Anesthesia was maintained with midazolam, sufentanyl, nitrous oxide and
isoflurane. All patients were monitored invasively and admitted to the intensive care unit after surgery.
Isolated Limb Perfusion.
The perfusion technique used at the Groningen University Hospital is based on the technique developed
by Creech and Krementz [16]. Briefly, after ligation of all collateral vessels and heparinization of the
patient with 3.3 mg heparin/kg (Thromboliquine
R, Organon BV, Oss, the Netherlands) the axillary,
iliac, femoral or popliteal vessels were dissected, cannulated and connected to the extracorporeal
circuit. The perfused limb was wrapped in a thermal blanket to reduce heat loss and four thermistor
probes were inserted subcutaneously and intramuscularly for continuous monitoring of the temperature
during perfusion. A tourniquet was applied to the proximal limb in an attempt to minimize leakage of
the perfusate into the systemic circulation through skin collaterals. Perfusion was performed for 90
minutes under mildly hyperthermic conditions (39-40 
0C). The perfusate consisted of 350 ml 5%
dextran 40 in glucose 5% (Isodex
R, Pharmacia AB, Uppsala, Sweden), 500 ml blood (250 ml red blood
cells, 250 ml plasma), 30 ml 8.4% NaHCO3 and 0.5 ml 5000 IU/ml heparin (Thromboliquine
R). The
perfusate was oxygenated with a bubble oxygenator and driven by a roller pump. At the start of
perfusion r-TNF-a (Boehringer Ingelheim, Germany, 4 mg for leg perfusions and 3 mg for arm
perfusions) was injected as a bolus into the arterial line of the perfusion circuit. Melphalan (Burroughs
Wellcome, London, England, 10 mg/L volume of an affected leg and 13 mg/L volume of an affected
arm) was administered 30 minutes later. Pretreatment with r-IFN-g consisted of a daily subcutaneous
injection with 0.2 mg r-IFN-g (Boehringer, Germany) on the two days preceding the perfusion and a
bolus injection of 0.2 mg r-IFN-g into the perfusion circuit. During perfusion potential leakage to the
systemic circulation was monitored with I
131 -labeled albumin [6]. After 90 minutes of perfusion, theEffects of isolated limb perfusion with TNF-a on sytemic fibrinolysis
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limb was flushed with 2 L dextran 40 in glucose 5% (Isodex
R) and 500 ml blood (250 ml red blood
cells, 250 ml plasma), catheters were removed, the circulation was restored and the heparin was
antagonized with protamine chloride. A lateral fasciotomy of the anterior compartment of the lower leg
(in leg perfusions) or a fasciotomy of the forearm (in arm perfusions) was performed to prevent a
compartment syndrome.
Blood samples.
Blood samples were drawn from an indwelling radial artery line before cannulation (t=0), 5 min after
starting perfusion (t=1), 1 min before ending perfusion (t=2), 5 min after normal circulation was
restored (t=3), 2 hours thereafter (t=4) and finally after 24 hours (t=5). Samples were collected in
either EDTA Stabylite Vacutainer
R tubes or in citrate-containing tubes, and kept on melting ice during
transport to the laboratory. Samples were centrifuged for 10 min at 3000 g at 0
oC. Plasma was stored
at -80
oC until analysis.
Immunochemical Analyses.
TNF-a levels were determined by specific immunoradiometric assay (Medgenix Diagnostics,
Soesterberg, the Netherlands). Samples were processed according to the guidelines of the
manufacturer. FbDP were measured with an ELISA (Fibrinostika FbDP, Organon Teknika, Turnhout,
Belgium) and PAP with an ELISA (EIA APP micro, Behringwerke AG, Marburg, Germany). t-PA
antigen was measured with an ELISA (Asserachrom tPA, Stago, Boehringer, Mannheim, Germany). t-
PA activity was determined in a bioassay (Chromolize-t-PA, Biopool, Umeå, Sweden). PAI-1 antigen
was measured with an ELISA (Innotest-PAI-1, Innogenetics, Antwerp, Belgium).
Normal values for FbDP and PAP ranged from 90 - 500 ng/ml and from 80 - 470 mg/L respectively.
Normal ranges, as indicated by the manufacturer, for t-PA antigen, t-PA activity and PAI-1 antigen
ranged from 0 - 5 ng/ml, from 0.0 - 1.0 IU/ml and from 0 - 40 ng/ml respectively.
Statistical Analysis.
Data were analyzed using SPSS for MS WINDOWS (release 5.0). The overall effect of perfusion with
TNF-a on each separate parameter of fibrinolysis was assessed by comparing differences from
baseline values (D FbDP, D PAP, D t-PA, D PAI-1) between TNF-a treated patients and controls,
using a Kolmogorov-Smirnov test for nonparametrically distributed values. Differences in each
separate parameter at different time points between TNF-a treated patients and controls were assessed
with a Mann Whitney U rank sum test for nonparametrically distributed values. A p-value <0.05 was
considered significant.Chapter IV
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Results
All patients who received r-TNF-a showed an increase in systemic TNF-a-levels (Figure 1).
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Fig. 1.Mean systemic TNF-a a-levels in r-TNF-a a treated patients (closed circles) and in controls (open
circles) over time. Hyperthermic isolated limb perfusion is indicated by the black box.
Statistically significant differences are marked with an asterisk (*). Error bars represent
standard deviation.
Systemic levels of TNF-a varied over a wide range, but mean values were significantly higher in the r-
TNF-a-treated group (mean maximum TNF-a-levels 87227 ng/L versus 31 ng/L in controls,
p<0.002). Peak levels were reached just before the end of perfusion or 5 min after recirculation.
Overall levels of mean t-PA activity were higher in the r-TNF-a group (p < 0.02 Figure 2).
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Fig. 2 Mean t-PA activity in r-TNF-a a treated patients (closed circles) and in controls (open circles)
over time. Hyperthermic isolated limb perfusion is indicated by the black box. Statistically
significant differences are marked with an asterisk (*). Error bars represent standard
deviation.
Mean levels ranged from 0 to 6 IU/ml. t-PA activity in the r-TNF-a-treated group peaked during
perfusion; 2 hours later no t-PA activity could be demonstrated.Effects of isolated limb perfusion with TNF-a on sytemic fibrinolysis
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t-PA antigen levels were also higher in r-TNF-a-treated patients than in controls (p < 0.01) and
remained elevated for 2 hours after perfusion (Figure 3).
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Fig. 3 Mean t-PA antigen levels in r-TNF-a a treated patients (closed circles) and in controls (open
circles) over time. Hyperthermic isolated limb perfusion is indicated by the black box.
Statistically significant differences are marked with an asterisk (*). Error bars represent
standard deviation.
Individual time point differences were significant at t=3 (5 min after normal circulation was restored, p
< 0.01) and at t=4 (2 hours after ending the perfusion, p < 0.03).
After activation of the fibrinolytic system in the r-TNF-a-perfused group, a sharp rise in PAI-1 antigen
was observed (Figure 4).
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Fig. 4 Mean PAI-1 levels in r-TNF-a a treated patients (closed circles) and in controls (open circles)
over time. Hyperthermic isolated limb perfusion is indicated by the black box. Statistically
significant differences are marked with an asterisk (*). Error bars represent standard
deviation.
Mean levels ranged between 50 and 1652 ng/ml. Overall levels were higher in the r-TNF-a-treated
group (p < 0.005). The peak level was observed 2 hours after the end of perfusion. For individual timeChapter IV
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points differences were significant at t=3 (5 min after normal circulation was restored, p< 0.05) and at
t=4 (2 hours after ending the perfusion, p < 0.02).
There were definite signs of activation of the fibrinolytic system in the group perfused with r-TNF-a.
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Fig. 5 Mean PAP-levels in r-TNF-a a treated patients (closed circles) and in controls (open circles) over
time. Hyperthermic isolated limb perfusion is indicated by the black box. Statistically significant
differences are marked with an asterisk (*). Error bars represent standard deviation.
Mean PAP levels ranged from 200 to 1500 mg/l. Overall, PAP levels were higher in the r-TNF-a-
perfused group (p < 0.03, Figure 5).
For individual time points differences were significant at t=2 (end of perfusion, p < 0,01), t=3 (5 min
after normal circulation was restored, p < 0.005) and t=4 (2 hours after ending the perfusion, p<0.05).
PAP levels returned to baseline at 24.hours.Effects of isolated limb perfusion with TNF-a on sytemic fibrinolysis
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Fig. 6 Mean FbDP levels in r-TNF-a a treated patients (closed circles) and in controls (open circles) over
time. Hyperthermic isolated limb perfusion is indicated by the black box. Statistically significant
differences are marked with an asterisk (*). Error bars represent standard deviation.
FbDP levels in r-TNF-a-treated patients and in controls showed a similar course (Figure 6). Median
levels ranged from 250 ng/ml to 3000 ng/ml. Overall levels were higher in the r-TNF-a-treated group
(p < 0.03). Differences for individual time points were significant at t=3 (5 min after normal
circulation was restored, p < 0.05). Due to large differences in FbDP levels between individual patients
in the r-TNF-a-treated group, no significant changes in mean FbDP level within this group could be
demonstrated once normal circulation was restored.
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Fig. 7 Correlation between maximum systemic TNF-a a levels (log scale) and maximum systemic PAI-1
levels (2 hours post-perfusion) in r-TNF-a a treated patients (closed circles) and controls (open
circles).
Figure 7 shows the relationship between maximum TNF-a-levels, measured from arterial blood, and
PAI-1 antigen levels at t=4 (2 hours post-perfusion), which were invariable the highest PAI-1 levels
recorded in the study. There was a weak but statistically significant relationship (p < 0.05, r=0,4).Chapter IV
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Individual data on maximum systemic TNF-a-levels, FbDP at t=3 and t-PA antigen, PAP and PAI-1
antigen at t=4 are shown in Table 1.
Patient nr Patient nr
TNF- TNF- a a
ng/L ng/L
(normal: 0-15) (normal: 0-15)
FbDP FbDP
ng/mL ng/mL
(normal: 90-500) (normal: 90-500)
tPA antigen tPA antigen
ng/mL ng/mL
(normal: 0-5) (normal: 0-5)
PAP PAP
m mg/mL g/mL
(normal: 80-470) (normal: 80-470)
PAI PAI
ng/ml ng/ml
(normal: 0-40) (normal: 0-40)
1 1 4,328 4,328 537 537 149 149 537 537 995 995
2 2 135,242 135,242 3,298 3,298 46 46 1,806 1,806 4,870 4,870
3 3 5,325 5,325 2,997 2,997 83 83 1,812 1,812 1,489 1,489
4 4 9,400 9,400 1,945 1,945 53 53 1,750 1,750 2,107 2,107
5 5 283,500 283,500 465 465 35 35 881 881 2,264 2,264
6 6 82,000 82,000 3,494 3,494 100 100 2,426 2,426 3,707 3,707
7 7 29,000 29,000 1,935 1,935 60 60 1,978 1,978 2,198 2,198
8 8 51,100 51,100 2,649 2,649 89 89 3,906 3,906 1,665 1,665
9 9 6,096 6,096 522 522 75 75 471 471 635 635
10 10 546,000 546,000 796 796 38 38 946 946 1,793 1,793
11 11 157,000 157,000 9,978 9,978 79 79 2,486 2,486 1,917 1,917
12 12 22,300 22,300 511 511 52 52 466 466 1,239 1,239
13 13 1,393 1,393 428 428 37 37 176 176 88 88
14 14 3,850 3,850 682 682 66 66 948 948 1,703 1,703
15 15 10,878 10,878 295 295 55 55 202 202 371 371
16 16 134,000 134,000 1,059 1,059 50 50 1,388 1,388 626 626
17 17 3,347 3,347 467 467 44 44 253 253 236 236
18 18 8,039 8,039 484 484 63 63 1,039 1,039 2,155 2,155
19 19 4,491 4,491 678 678 66 66 580 580 391 391
20 20 267,000 267,000 3,712 3,712 38 38 1,867 1,867 2,604 2,604
Control 1 Control 1 30 30 522 522 34 34 301 301 443 443
Control 2 Control 2 51 51 198 198 15 15 293 293 47 47
Control 3 Control 3 3 3 335 335 32 32 208 208 250 250
Control 4 Control 4 44 44 999 999 24 24 371 371 103 103
Table 1 Individual values of maximum systemic TNF-a a, FbDP (t=3), t-PA antigen (t=4), PAP (t=4) and
PAI-1 antigen (t=4) in patients and in controls.
Finally, patients additionally treated with r-IFN-g had levels of TNF-a, t-PA activity and antigen, PAP
and PAI-1 antigen that did not differ significantly from values recorded in patients who received r-
TNF-a without additional treatment with r-IFN-g.
Discussion
TNF-a, originally defined by its anti tumor activity in vivo, is now recognized to play a key role as a
polypeptide mediator in the pathogenesis of septic shock [17-23]. It has also been reported to
profoundly influence the dynamic balance between procoagulant and fibrinolytic factors in the blood.
In the study presented here we have measured parameters of fibrinolysis in patients undergoing
isolated limb perfusion with r-TNF-a. Perfusion with r-TNF-a, in combination with r-IFN-g and
melphalan, has recently been shown to yield high remission rates in patients with irresectable extremity
soft tissue sarcomas and in patients with melanoma in-transit metastases. In a multicenter study of 55
patients with irresectable soft tissue sarcoma, a major tumor response was seen in 87% of the patients,
rendering the tumor resectable in most cases [4]. Fraker and coworkers have recently reported a series
of 38 patients with extremity melanoma with a complete response rate of 76% and an overall objective
response rate of 92% [5]. Unfortunately, this type of treatment is not without systemic effects: due to
leakage from the perfusion circuit a high, but short-lived peak in systemic TNF-a is observed duringEffects of isolated limb perfusion with TNF-a on sytemic fibrinolysis
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and immediately after perfusion [11, 12]. We have found evidence of an initial enhancement of
fibrinolytic activity as documented by a modest increase of PAP-levels and FbDP with a peak towards
the end of perfusion and immediately following recirculation. The five-fold increase in t-PA activity,
preceding the increase in PAP and FbDP, was of the same order of magnitude as has been described in
prior studies [24, 25]. The most striking finding of our study was a sharp rise in PAI-1 antigen, that
followed the increase in t-PA antigen. Its peak was reached at 2 hours after perfusion. At that time
levels of t-PA activity fell dramatically, while t-PA antigen could be detected for many hours. The
highest PAI-1 antigen levels were found in patients with the highest maximum systemic TNF-a levels.
PAI-1 antigen levels in our perfusion model were 10 to 20 times higher than levels described in earlier
studies with a different design [24, 25].
These data show that isolated limb perfusion with r-TNF-a results in high levels of TNF-a in
systemic blood during and immediately after perfusion, which cause initial activation of fibrinolysis
due to increase of t-PA antigen and activity. Subsequently, fibrinolysis is inhibited by a more
pronounced increase in PAI-1 antigen with a simultaneous fall in t-PA activity, probably due to
binding of t-PA to PAI-1. The increase in PAI-1 antigen is proportional to the maximum level of TNF-
a, measured in the systemic arterial circulation of the patient. A similar two-stage response has been
described in experimental and clinical sepsis, where TNF-a is also of pivotal importance [26-30]. The
overall inhibitory effect on fibrinolysis in the septic patient is hypothesized to contribute to end-organ
damage by disseminated intravascular coagulation, which is a frequent and severe complication of
sepsis [15, 30, 31]. Although t-PA activity was not detectable at 2 hours after the start of perfusion,
PAP levels were still elevated at that time, suggestive of ongoing formation of plasmin. This could be
due either to a delayed clearance of PAP or to release from the tumor which was visibly necrotic at this
stage. Pretreatment with r-IFN-g did not influence any of the measured parameters of fibrinolysis in a
statistically significant way.
The precise mechanism of the early increase in fibrinolysis remains unclarified by this study. A
direct effect of TNF-a on endothelial cells to produce t-PA has been proposed, although in vitro effects
are variable and dose dependent [25]. Alternatively, van Hinsbergh and coworkers have suggested that
thrombin, generated by activation of the coagulation cascade, rather than TNF-a, is the actual trigger
for the increased level of t-PA during treatment with r-TNF-a [32]. Our experiments have shown an
increase in t-PA during the perfusion phase of the study, when the patients were adequately
heparinized. This effectively rules out the presence of relevant amounts of circulating thrombin.
Although it cannot be excluded that TNF-a induces generation of thrombin bound to endothelial cells,
a direct effect of TNF-a on vascular endothelial cells would seem a more probable explanation. This
conclusion is supported by experiments in chimpanzees, where the effects of TNF-a on fibrinolysis
were not influenced by the administration of a monoclonal antibody against tissue factor, suggesting
that the triggering of the fibrinolytic response was not dependent on the generation of thrombin, but a
direct effect of TNF-a [33].
The large increase in PAI-1 antigen levels is probably also due to a direct effect of TNF-a on
vascular endothelium. Increased production of PAI-1 antigen following incubation with TNF-a has
been shown in human umbilical vein endothelial cells, in human umbilical artery endothelial cells and
in human foreskin vascular endothelial cells [34, 35]. Rats treated intraperitoneally with human r-TNF-
a showed a dose-dependent increase in PAI-1 activity [35, 36].
Silverman et al. have reported on cancer patients treated in various regimens with intravenously
administered r-TNF-a, who reacted with a significant rise in t-PA activity, followed by a
corresponding increase in PAI-1 activity [24]. After a 2 hour infusion with r-TNF-a all fibrinolyticChapter IV
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parameters returned to pretreatment values within 24 hours. Van Hinsbergh et al. have measured
several indexes of fibrinolysis at 3 and 24 hours after a 24 hour continuous infusion of r-TNF-a in
cancer patients. Fibrin- and fibrinogen degradation products as well as PAP complexes were increased
after 24 hours [32]. Baars et al. could show that injection of interleukin-2 in cancer patients induced
changes in fibrinolysis similar to those induced by r-TNF-a [37]. Van der Poll et all [25] described a
series of six healthy human volunteers, treated with a single intravenous injection of 50 mg/m
2 r-TNF-
a. A sharp rise in t-PA activity was observed reaching its maximum at 1 hour. Plasma levels of PAI-1
antigen did not change in the first hour following r-TNF-a administration, but peaked sharply
thereafter, with a maximum PAI-1 level attained at 3 hours. D-dimer levels were also increased,
reaching a summit after 1 hour and PAP-levels increased transiently with a peak at 45 min. The
authors concluded that injection of r-TNF-a induces a rapid activation and a subsequent inhibition of
the fibrinolytic system in human volunteers [25].
In the study presented here the effects of TNF-a on fibrinolysis were analyzed in an entirely
different model. It also differs from earlier studies by Silverman [24] and van Hinsbergh [32] in that its
design includes a control group treated in exactly the same way but without the use of r-TNF-a.
Although TNF-a levels were not reported in the study of van der Poll on fibrinolysis [25], their study
on coagulation [38], performed in the same small group of healthy volunteers, yielded mean peak TNF-
a levels of 4261 ± 785 pg/ml. Peak TNF-a levels recorded in our patients were twice as high (mean
maximum TNF-a 87227 ng/L. Moreover, high TNF-a levels persisted for much longer in our study.
Our study has several limitations. The control group of patients treated with perfusion with
melphalan but without r-TNF-a was small and patients were not randomly assigned to either treatment
arm. Due to its dramatic effects on tumor regression, perfusions without r-TNF-a came to be
considered ethically unjustified. Obviously, this made any form of randomization impossible. Another
source of variation is the variable extent to which leakage of r-TNF-a from the perfusion circuit to the
systemic circulation occurred. This is reflected in widely varying levels of peak systemic TNF-a (range
1393 to 546000 ng/L). Such variation is inherent in the perfusion / leakage model used in these
experiments. The response of parameters of fibrinolysis however was remarkably uniform in all
patients.
 It may well be that, in the treatment of cancer with r-TNF-a, the effects of this cytokine on
coagulation and fibrinolysis are important for its antitumor potential. Tumor vasculature seems to be
disproportionally sensitive to TNF-a, and vascular destruction precedes regression of the tumor in
many cases [39]. However, as our experiments have shown, even with the technique of isolated limb
perfusion an inhibition of the systemic fibrinolytic system, by a large increase of PAI-1 and decrease of
t-PA activity, cannot be prevented, which might prove to be detrimental. As in sepsis, it may place the
patient at danger of extensive deposition of thrombi in the systemic microvasculature and subsequent
damage to multiple organ systems, especially if activation of the coagulation system occurs at the same
time.
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Summary
Hyperthermic isolated limb perfusion (HILP) with recombinant TNF-a (r-TNF-a) and melphalan has
been shown to result in a sepsis like syndrome due to leakage of r-TNF-a from the perfusion system to
the systemic circulation. We have studied renal function parameters in 11 cancer patients, who
underwent 12 perfusions. Three patients, perfused with melphalan only, served as controls. All patients
treated with r-TNF-a developed a sepsis syndrome and needed volume replacement and inotropes to
remain normotensive; controls had an uneventful postoperative course. Creatinine clearance decreased
transiently on the day of perfusion in both groups (mean preperfusion clearance 118 ml/min, mean
postperfusion clearance 68 ml/min, p<0.02, n=15). Follow-up measurements of renal plasma flow and
glomerular filtration rate in 9 r-TNF-a treated patients did not suggest permanent damage. One patient
became hypotensive and developed transient multiple organ dysfunction with renal failure needing
hemofiltration. In r-TNF-a treated patients, but not in controls, a transient increase in clearance of b2
microglobulin (49 vs. 8171 ml/min, p<0.001) and urinary excretion of phosphate (12 vs. 48 mmol/L,
p<0.05) was seen, compatible with proximal tubular dysfunction. These data suggest that HILP with
melphalan decreases glomerular function, whether or not r-TNF-a is added to the perfusion circuit.
Extension of the treatment regimen with r-TNF-a may result in additional proximal tubular
dysfunction. If hypotension can be avoided this deterioration in renal function seems to be transient,
with full recovery within weeks.Renal function in isolated limb perfusion with TNF-a
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Introduction
Impairment of renal function is a frequent complication of septic shock, with a major impact on
outcome. Its occurrence is at least partly explained by a decrease in renal blood flow secondary to a
drop in arterial blood pressure. Additionally, cytokines like tumor necrosis factor alpha (TNF-a),
which are released systemically and locally during bacterial sepsis, may directly compromise renal
function.
Recently, hyperthermic isolated limb perfusion with melphalan and human recombinant TNF-a (r-
TNF-a) has been studied in patients with locally advanced soft tissue tumors and advanced melanomas
of a limb, as an alternative to amputation. The technique of isolated limb perfusion allows the
administration of high doses of these agents locally while minimizing systemic toxicity. However, it has
been recognized by us as well as by others that isolated limb perfusion with r-TNF-a induces a sepsis
like state in all patients, characterized by fever, tachycardia and a low blood pressure due to systemic
vasodilation [1,2]. The occurrence of this syndrome is explained by leakage of r- TNF-a from the
perfused limb into the systemic circulation; very high levels of TNF-a have been documented in
peripheral blood of these patients during and directly following perfusion. Leakage has been confirmed
by adding radiolabeled albumin to the perfusate; radioactivity can be traced to the systemic circulation
during perfusion treatment [3].
In view of the similarity of this clinical syndrome to bacterial sepsis and the unexpectedly high
systemic levels of TNF-a, a detrimental effect on kidney function could be anticipated. This study was
undertaken to assess the impact of isolated limb perfusion with r-TNF-a and melphalan on creatinine
clearance, renal plasma flow (ERPF) and glomerular filtration rate (GFR). Fractional excretion of
sodium (FENa) and urinary excretion of b2 microglobulin and phosphate were determined to assess
proximal tubular function.
Patients and methods
Outline of Experiments
Creatinine clearance and excretion of b2 microglobulin and phosphate were determined in patients
undergoing hyperthermic isolated limb perfusion with r-TNF-a and melphalan. The results were
compared with data obtained in control patients who underwent a similar perfusion procedure but
without the addition of r-TNF-a. In a subgroup of r-TNF-a treated patients ERPF and GFR were
determined with radiopharmaceuticals prior to the perfusion. These experiments were repeated after the
perfusion. Due to background radioactivity from radio-labeled albumin administered during the
perfusion, postoperative renal function measurement had to be postponed with an average of 22 days
(range 10-31).
Anesthesia and Intensive Care
Anesthesia was induced with thiopental, after which the patients were paralyzed with vecuronium and
the trachea intubated. Anesthesia was maintained with midazolam, sufentanyl, nitrous oxide and
isoflurane. After induction arterial and pulmonary artery catheters were inserted. Blood pressure, ECG,
urine output, venous and pulmonary pressures, as well as pulmonary wedge pressures and blood gas
values were checked at standard intervals. Fluid resuscitation with crystalloid and colloid solutions was
given to maintain pulmonary wedge pressures above 12 mmHg and a dopamine infusion was added ifChapter V
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systolic arterial blood pressure fell to 90 mmHg or decreased by > 30 mmHg from preoperative values
despite adequate fluid replacement. All patients were admitted to the intensive care unit following
surgery, where the same algorithm was followed to prevent hypotension. Patients received mechanical
ventilation until hemodynamically stable.
Hyperthermic Isolated Limb Perfusion
The perfusion technique employed at the Groningen University Hospital is based on the technique
developed by Creech and Krementz [4]. Briefly, after ligation of all collateral vessels and
heparinization of the patient with 3.3 mg heparin/kg bodyweight (Thromboliquine, Organon BV, Oss,
the Netherlands) the axillary, iliac, femoral or popliteal vessels were dissected, cannulated and
connected to the extracorporeal circuit. A tourniquet was applied to the proximal limb in an attempt to
minimize leakage of the perfusate into the systemic circulation through skin collaterals. Perfusion was
performed under mild hyperthermic conditions (39-40
0C). The perfusate consisted of 350 ml 5%
dextran 40 in glucose 5% (Isodex, Pharmacia AB, Uppsala, Sweden), 500 ml blood (250 ml red blood
cells, 250 ml plasma), 30 ml 8.8% NaHCO3 and 0.5 ml 5000 IU/ml heparin (Thromboliquine). The
perfusate was oxygenated with a bubble oxygenator and driven by a roller pump. At the start of
perfusion recombinant human TNF-a (Boehringer, Ingelheim, Germany, 4 mg for leg perfusions and 3
mg for arm perfusions) was injected as a bolus into the arterial line of the perfusion circuit. Melphalan
(Burroughs Wellcome, London, England, 10 mg/L volume of an affected leg and 13 mg/L volume of
an affected arm) was administered 30 minutes later. After 90 minutes of perfusion, the limb was
flushed with 2 L dextran 40 in glucose 5% (Isodex) and 500 ml blood (250 ml red blood cells, 250 ml
plasma), catheters were removed, the circulation was restored and the heparin antagonized with
protamine chloride.
Measurement of TNF-a
TNF-a was measured in blood drawn from the radial artery by specific immunoradiometric assay
(Medgenix Diagnostics, Soesterberg, the Netherlands). Samples were processed according to the
guidelines of the manufacturer.
Measurement of renal function parameters
GFR and ERPF were measured simultaneously using 
125I-iothalamaat and 
131I-hippurate, respectively,
according to the method described by Donker et al. [5]. The radiopharmaceuticals were infused at a
constant rate after a priming dose was given. After an equilibration period of one and a half hour,
clearances were determined over a two hour period. Post-operative testing was performed at an average
of 22 days (SD 6 days) after perfusion. Creatinine clearances were determined from 24 hour urine
collections.
Statistical Analysis
Data were analyzed using SPSS for MS WINDOWS (release 5.0). Differences in mean values within
groups were studied with either a t-test for paired differences (sytemic vascular resistance, creatinine
clearance) or a Wilcoxon Matched Pairs Signed-Ranks Test (ERPF, GFR, urinary excretion of b2
microglobulin, serum levels of b2 microglobulin, clearance of b2 microglobulin, urinary excretion of
phosphate), depending on the assumption of distribution. Differences between groups were studied with
either an independent samples t-test (creatinine clearance) or a Mann-Whitney U-Wilcoxon Rank Sum
W Test (serum levels of b2 microglobulin, urinary excretion of b2 microglobulin and FENa).Renal function in isolated limb perfusion with TNF-a
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Bonferroni's method was used to correct for the effect of multiple comparisons. For single testing a p-
value <0.05 was considered significant.
Results
Between September 1992 and May 1993 twelve consecutive hyperthermic isolated limb perfusions
with r-TNF-a and melphalan were studied in eleven patients. Three patients, perfused with melphalan
but without r-TNF-a served as controls. Paired data on renal blood flow and glomerular filtration rate
were available in seven and nine perfusions respectively.
Peak systemic TNF-a concentrations in patients treated with r-TNF-a ranged from 4328 ng/L to
267000 ng/L with a median of 16969 ng/L and a mean of 67693 ng/L. Maximum TNF-a
concentrations were reached at the end of the perfusion procedure.
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Fig. 1  Mean arterial pressure (MAP, open rectangles), systemic vascular resistance (SVR, closed
rectangles) and dopamine requirement (crosses) in patients treated with r-TNF-a a perfusion.
The asterisk (*) illustrates a significant decrease in SVR compared to baseline values (p<0.005).
Error bars represent standard deviations.
Figure 1 shows the effects of r-TNF-a perfusion on systemic vascular resistance, mean arterial
pressure and the average need for dopamine. In the r-TNF-a-treated group mean systemic vascular
resistance decreased from 854 dyne/sec/cm
-6 preperfusion to a nadir of 423 dyne/sec/cm
-6 postperfusion
(p<0.005). Mean arterial pressure was not significantly decreased at any moment; the lowest mean
arterial pressure recorded was 60 mm Hg. All but one r-TNF-a treated patient needed treatment with
dopamine to maintain bloodpressure after adequate volume resuscitation (maximum dose 12
mg/kg/min). This patient, and 3 others, were treated with norepinephrine. None of the control patients
needed postoperative care in the ICU and none of them were treated with dopamine and/or
norepinephrine postoperatively.Chapter V
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Fig. 2 Mean creatinine clearance in patients treated with r-TNF-a a perfusion (solid line) and in
controls (dotted line). The asterisk (*) illustrates a significant decrease in creatinine clearance
in both groups compared to baseline values (p<0.02). Error bars represent standard deviations.
Preperfusion serum creatinine levels ranged from 67-90 mmol/L (mean 80 mmol/L). All patients,
including controls, showed a transient drop in creatinine clearance within 48 hours following perfusion
(Figure 2). Mean creatinine clearance decreased from a preperfusion level of 118 ml/min to a nadir of
68 ml/min on the second day after the perfusion (p<0.02). There was no significant difference in
creatinine clearance between r-TNF-a treated patients and controls. Creatinine clearance had returned
to normal in all patients on day 4, except in one patient who maintained a septic hemodynamic pattern
and developed multiple organ failure.
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Fig. 3 Box and whiskers plot showing effective renal plasma flow (ERPF), standardized for body
surface area, before and after perfusion with r-TNF-a a.Renal function in isolated limb perfusion with TNF-a
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Fig. 4 Box and whiskers plot showing glomerular filtration rate (GFR), standardized for body surface
area, before and after perfusion with r-TNF-a a.
Figure 3 and 4 show pre- and postperfusion values in r-TNF-a treated patients for ERPF (n=7)
and GFR (n=9) respectively; no significant differences were observed in any of these paired
parameters.
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Fig. 5 Urinary excretion of b b2 microglobulin in patients treated with r-TNF-a a perfusion (solid line) and
in controls (dotted line). The asterisks (*) illustrate a significant increase in b b2 microglobulin
excretion in the r-TNF-a a -treated group compared to baseline values (p<0.01). Numbers represent
median values.
In the r-TNF-a treated group there was an increase in the excretion of b2-microglobulin in the
urine from a median value of 41 mg/24 h preoperatively to a median value of 36727 mg/24 h one day
postperfusion (p<0.01, Figure 5). In serum, b2-microglobulin concentrations in this group rose from a
mean preperfusion value of 1416 mg/L to a mean one day postperfusion value of 3060 mg/L (p<0.01,
Figure 6).Chapter V
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Fig. 6 Mean serum levels of b b2 microglobulin in patients treated with r-TNF-a a perfusion (solid line)
and in controls (dotted line). The asterisks (*) illustrate a significant increase in serum b b2
microglobulin concentrations in the r-TNF-a a-treated group compared to baseline values
(p<0.01). Error bars represent standard deviations.
Clearance of b2-microglobulin in patients perfused with r-TNF-a increased from 49 ml/min pre-
operatively to 8171 ml/min one day postperfusion (p<0.001). In the control group neither urinary
excretion of b2-microglobulin, nor serum concentrations of b2-microglobulin changed significantly over
time (Fig 5 and 6). On the first day after perfusion, levels of b2-microglobulin in serum, as well as
urinary excretion of b2-microglobulin, were significantly higher in the r-TNF-a treated patients than in
controls (p<0.05). Preoperative values were not significantly different.
In r-TNF-a perfused patients urinary excretion of phosphate increased from a mean pre-operative
value of 12 mmol/24 h to a mean value of 48 mmol/24 h on day 2 after perfusion (p<0.05). If
corrected for sodium excretion this difference was no longer significant.
FeNa increased from a preperfusion level of 0.4% to 1.1% on day 1 after perfusion with r-TNF-a,
but this increase failed to reach statistical significance (p=0.07).
Discussion
This study describes a group of cancer patients who were inadvertently exposed to high systemic
concentrations of TNF-a and developed signs of sepsis syndrome as a result. Exposure to TNF-a
occurred as a side effect of hyperthermic isolated limb perfusion with r-TNF-a, through leakage of this
antitumor cytokine from the perfusion circuit to the systemic circulation. The mean maximum systemic
TNF-a concentration in r-TNF-a treated patients was 67693 ng/L (range 4328 to 267000 ng/L). This
is several orders of magnitude higher than TNF-a concentrations previously reported in different forms
of shock. In a series of 79 patients with meningococcal disease and/or septicemia all patients with
TNF-a levels over 100 ng/L died [6]. In septic shock median TNF-a concentrations of 120 ng/L have
been reported [7]. Despite much higher concentrations of TNF-a all our patients survived their ICU
stay and could be discharged to the ward after a median stay in the ICU of two days.
The effects of TNF-a on the kidney have not yet been well characterized. TNF-a is an early
mediator of endotoxemic shock and, if administered to laboratory animals, causes a clinical syndromeRenal function in isolated limb perfusion with TNF-a
73
which is very similar to bacterial sepsis [8]. In this setting, part of the effect of TNF-a on the kidney
will be through decreased mean arterial pressure and decreased renal perfusion. However, there may
also be a direct effect of TNF-a on kidney function. Rabbits given recombinant human TNF-a showed
a decrease in renal blood flow, but also a decrease in the renal fraction of aortic blood flow, caused by
a 17% increase in renal resistance [9]. Autoregulation was preserved as indicated by a compensatory
increase of the filtration fraction with 17%. Hemodynamic changes were abolished by both
thromboxane inhibitors and indomethacin, implying a role for the arachidonate cascade system. In
another rabbit model TNF-a induced swelling of glomerular endothelial cells and accumulation of
leukocytes in the glomerular capillary lumen [10]. In a plethora of animals models, local TNF-a
production, mainly by mesangial cells, has been shown to play a role in the pathophysiology of
inflammatory kidney disease [11- 13]. TNF-a is also involved in kidney transplant rejection [14].
Experiments in humans have been limited by the toxicity of TNF-a. Early trials with intravenous TNF-
a have reported renal toxicity in sporadic cases [15], but normal kidney function is the rule [16]. In
patients who underwent isolation perfusion with r-TNF-a Eggimann and coworkers reported a fall in
creatinine clearance in 22% of their patients [1]. In a group of 9 patients reported by Sorkin and
coworkers, 2 patients showed a transient rise in serum creatinine [17].
In the present study all r-TNF-a treated patients showed a decrease in creatinine clearance on the
day of perfusion. There was a similar decrease in control patients, who were treated with melphalan
only. In both groups creatinine clearance returned to normal levels within two days. Subsequent
radiopharmaceutical studies in the r-TNF-a treated group did not show significant late changes in GFR
and ERPF. It should be noted that in all patients but one hypotension could be prevented with early
expansion of volume and judicious use of vasocactive drugs, guided by invasive haemodynamic
monitoring in the operating room as well as in the intensive care unit. One patient went on to develop
transient multiple organ failure. This patient remained inotrope-dependent with a septic hemodynamic
profile and developed acute respiratory failure and non-oliguric renal failure for which he had to be
treated with continuous veno-venous hemofiltration.
It appears from these data that hyperthermic isolated limb perfusion with melphalan as such
transiently decreases creatinine clearance. The role of r-TNF-a in this setting remains to be
determined. We were unable to show that the addition of r-TNF-a to the perfusion circuit resulted in
any additional loss of glomerular function. Peri- and postoperative hypotension, due to TNF-a-induced
systemic vasodilation, can be lifethreatening, and its management requires skill and experience.
Aggressive support of perfusion pressures with cristalloid and colloid infusions with vasopressors in an
ICU setting is mandatory to prevent the development of multiple organ dysfunction. In the series
described here, no permanent renal damage occurred if peri- and postoperative hypotension could be
avoided. In theory, this could be attributed to a specific protective effect of dopamine on the kidney.
However, proof that dopamine influences the course of acute renal failure is lacking. Furthermore, in
additional experiments in mechanically ventilated patients after aortic surgery, we were unable to show
a specific renal hemodynamic effect of this drug; the observed increase in RBF and GFR could be fully
ascribed to the increase in cardiac output [18].
On the day of perfusion, excretion of b2 microglobulin increased greatly in r-TNF-a treated
patients. There was a simultaneous rise in plasma b2 microglobulin, which has been recognized as a
TNF-a effect by others [19], but this was insufficient to explain the 150-fold increase in clearance of
b2 microglobulin. Like the creatinine clearance, clearance of b2 microglobulin returned to normal levels
within two days. Since b2 microglobulin is almost completely reabsorbed in the proximal tubule these
data suggest a temporary dysfunction of this proximal part of the nephron. The observed increase inChapter V
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phosphate excretion is compatible with such a temporary proximal dysfunction, although it could also
be explained by the observed increase in sodium excretion. An increase in sodium excretion in turn,
could be attributed to sodium loading, which was carried out to correct hypovolemia and to prevent
hypotension. Although FENa was >1% in the r-TNF-a treated group on day 1 postperfusion, a value
compatible with a diagnosis of acute tubular necrosis, it did not differ significantly from FENa in the
control group. Thus, the precise effect of r-TNF-a on proximal tubular function remains to be
determined.
The present study has several limitations. The control group of patients treated with perfusion with
melphalan but without r-TNF-a was small and patients were not randomly assigned to either treatment
arm. Due to its dramatic effects on tumor regression, perfusions without r-TNF-a became to be
considered ethically unjustified by the responsible clinicians. Obviously, this made any form of
randomization impossible. A second drawback of the study design is the interference of GFR and
ERPF measurements with standard I
131-albumin measurement of albumin leak during perfusion (as an
indicator of r-TNF-a leak to the systemic circulation), forcing us to postpone GFR and ERPF
measurements to well after the perfusion procedure. In theory early changes in renal function may thus
have been masked. However, to our knowledge this is the first study to examine the renal effects of
isolated limb perfusion with r-TNF-a in humans in some detail.
We conclude that, in hyperthermic isolated limb perfusion with r-TNF-a and melphalan, renal
toxicity is acceptable, even if considerable leakage of r-TNF-a to the systemic circulation of the patient
cannot be avoided. Although a transient decrease in creatinine clearance is observed, no lasting damage
to the kidney will occur if hemodynamic stability can be maintained. This requires early treatment with
volume expansion and pressor drugs, guided by invasive haemodynamic monitoring. If r-TNF-a is
added to the treatment a transient decrease of proximal tubular function is seen, in addition to the effect
on glomerular filtration. This may represent a direct nephrotoxic effect of TNF-a.
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Summary
This chapter aims to analyze the mechanism of vasodilation and circulatory shock in patients who were
treated with isolated limb perfusion with melphalan and recombinant tumor necrosis factor a (r-TNF-
a) for locally advanced malignant tumors. The role of nitric oxide, if any, was determined by
measuring plasma nitrite and nitrate levels.
Eight consecutive patients developed sepsis syndrome due to leakage of r-TNF-a from the perfusion
circuit to the systemic circulation. Despite the presence of very high systemic TNF- a levels during and
immediately after perfusion and definite signs of hyperdynamic circulatory shock (increased heart rate,
increased cardiac index, decreased systemic vascular resistance) nitrite and nitrate levels, measured in
plasma at several time points, were not elevated.
The hypothesis that, in humans, TNF-a induces vasodilation and shock through activation of inducible
nitric-oxide synthase and subsequent formation of excessive quantities of nitric oxide is not
substantiated by our results. Normal nitric oxide metabolite levels were found in the presence of high
TNF-a levels and shock. Other mechanisms that do not involve the nitric oxide pathway are likely to
play a role in the generation of hypotension and septic shock in this setting.Nitric oxide in isolated limb perfusion with TNF-a
79
Introduction
Isolated limb perfusion with melphalan and r-TNF-a, used in the treatment of locally advanced soft
tissue sarcomas or melanomas of a limb, has been shown to result in a severe, but short-lived sepsis
syndrome, characterized by fever, low blood pressure and the need for fluid resuscitation and inotropic
support [1,2]. The occurrence of this syndrome is explained by leakage of r-TNF-a from the perfusion
circuit into the systemic circulation; high levels of TNF-a are found in arterial blood during and
directly after the procedure. Since TNF-a can induce nitric oxide synthase leading to a sustained
release of nitric oxide and catecholamine-refractory vasodilation in animal models [3], we speculated
nitric oxide to be an important mediator of the circulatory shock observed in this setting. To test this
hypothesis we have measured metabolites of nitric oxide in eight patients during and after perfusion.
Subjects and Methods
Subjects
Eight patients received hyperthermic isolated limb perfusion at the division of surgical oncology of the
Groningen University Hospital after approval of the medical ethical committee and informed consent
had been obtained. Tumor histology is summarized in the table.
Normal values for nitrate and nitrite were obtained from studies in 26 healthy volunteers.
Anesthesia and intensive care
Anesthesia was induced with thiopental, after which the patients were paralyzed with vecuronium and
the trachea intubated. Anesthesia was maintained with midazolam, sufentanyl, nitrous oxide and
isoflurane. After induction a radial artery catheter and a pulmonary artery catheter were inserted.
Blood pressure, ECG, urine output, venous and pulmonary pressures, as well as pulmonary artery
wedge pressures and arterial blood gas values were checked at standard intervals. All patients were
admitted to the intensive care unit following surgery. Patients received mechanical ventilation until
hemodynamically stable. Fluid resuscitation with crystalloid and colloid solutions was given to
maintain pulmonary artery wedge pressures above 12 mm Hg, and a dopamine infusion was added if
systolic arterial blood pressure fell to 90 mm Hg or decreased by > 30 mm Hg from preoperative
values despite adequate fluid replacement.
Isolated Limb Perfusion
The perfusion technique employed at the Groningen University Hospital is based on the technique
developed by Creech and Krementz [4]. Briefly, after ligation of all collateral vessels and
heparinization of the patient with 3.3 mg heparin/kg bodyweight (Thromboliquine, Organon BV, Oss,
the Netherlands) the axillary, iliac, femoral or popliteal vessels were dissected, cannulated and
connected to the extracorporeal circuit. The perfused limb was wrapped in a thermal blanket to reduce
heat loss and four thermistor probes were inserted subcutaneously and intramuscularly for continuous
monitoring of the temperature during perfusion. A tourniquet was applied to the proximal limb in an
attempt to minimize leakage of the perfusate into the systemic circulation through skin collaterals.
Perfusion was performed during 90 minutes under mild hyperthermic conditions (39-40
oC). The
perfusate consisted of 350 ml 5% dextran 40 in glucose 5% (Isodex, Pharmacia AB, Uppsala,
Sweden), 500 ml blood (250 ml red blood cells, 250 ml plasma), 30 ml 8.4% NaHCO3 and 0.5 mlNitric oxide in isolated limb perfusion with TNF-a
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concentration of 10 mmol/L. Samples were further incubated for 5 min at 37
oC to oxidize nicotine
adenine dinucleotide phosphate (reduced), deproteinized, and assayed with Griess reagent as described
above. Values obtained by this procedure represent the sum of nitrite and nitrate. Nitrate
concentrations were obtained by subtracting nitrite concentration from the total nitrate + nitrite
concentrations.
Plasma samples for nitrate and nitrite measurements were taken at the following time points: 1 hour
before perfusion, during perfusion at 5, 30, 60 and 89 minutes and after perfusion at 5, 30, 60 minutes
and after 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours.
Samples were assessed for the presence of nitric oxide metabolites in two independent laboratories with
similar results.
Statistical analysis
Data were analyzed using SPSS for MS WINDOWS (release 5.0). To analyze differences in heart rate,
mean arterial pressure, cardiac output, systemic vascular resistance and TNF-a-levels before and after
perfusion the Wilcoxon Matched-Pairs Signed-Ranks Test was used. A p-value < 0.05 was considered
significant. To analyze the effect of perfusion on the sum of nitrate and nitrite an Analysis of Variance
was carried out, comparing patients and controls.
Results
Clinical details, TNF-a levels and nitric oxide metabolites of the patients are summarized in the table,
where the highest values of plasma TNF-a and the sum of nitrite and nitrate are shown.
Patient Patient Diagnosis Diagnosis Heart Rate Heart Rate Cardiac Index Cardiac Index Systemic Vascular Systemic Vascular
Resistance Resistance
TNF- TNF- a a NOx NOx
1 1 synovia synovia
sarcoma sarcoma
120 (76) 120 (76) 5.1 (2.9) 5.1 (2.9) 585 (1072) 585 (1072) 1393(43) 1393(43) 39.9 (22.2) 39.9 (22.2)
2 2 melanoma melanoma 100 (64) 100 (64) 5.5 (2.8) 5.5 (2.8) 334 (856) 334 (856) 38500(66) 38500(66) 35.4 (40.0) 35.4 (40.0)
3 3 synovia synovia
sarcoma sarcoma
150 (75) 150 (75) 8.0 (3.8) 8.0 (3.8) 429 (890) 429 (890) 21065(12) 21065(12) 22.2 (22.2) 22.2 (22.2)
4 4 liposarcoma liposarcoma 145 (75) 145 (75) 9.4 (3.9) 9.4 (3.9) 296 (749) 296 (749) 134000(1) 134000(1) 28.8 (33.2) 28.8 (33.2)
5 5 schwannoma schwannoma 140 (80) 140 (80) 5.8 (3.6) 5.8 (3.6) 572 (1119) 572 (1119) 17109(5) 17109(5) 35.0 (42.0) 35.0 (42.0)
6 6 histiocytoma histiocytoma 150 (110) 150 (110) 5.8 (3.6) 5.8 (3.6) 650 (908) 650 (908) 51000(10) 51000(10) 19.0 (18.6) 19.0 (18.6)
7 7 histiocytoma histiocytoma 155 (88) 155 (88) 6.2 (4.0) 6.2 (4.0) 501 (1000) 501 (1000) 8200 (1) 8200 (1) 32.2 (23.6) 32.2 (23.6)
8 8 melanoma melanoma 120 (66) 120 (66) 4.4 (2.2) 4.4 (2.2) 627 (927) 627 (927) 267000(65) 267000(65) 34.6 (24.9) 34.6 (24.9)
Table 1: Clinical details, peak systemic TNF-a a levels and nitric oxide metabolites. Tumor necrosis
factor a a is abbreviated as TNF-a a, the sum of plasma nitrite and nitrate as Nox. Values are
presented as highest value after perfusion (heart rate, cardiac index, TNF-a a, NOx), or lowest
value after perfusion (systemic vascular resistance), while the value 1 hour before perfusion is
given between brackets.Chapter VI
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Fig. 1 The black rectangles (dotted line) show the change in mean systemic vascular resistance (SVR)
with time. The open rectangles (interrupted line) show the mean cardiac output (CO). The
open circles (solid line) represent the mean sum of nitrite and nitrate (NOx). Hyperthermic
isolated limb perfusion was started at time point 0 and stopped after 1.5 hrs. as indicated by
the large closed triangle. Error bars represent standard deviation.
Figure 1 shows the course of mean systemic vascular resistance, cardiac output and mean nitrite +
nitrate levels over time.
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Fig. 2 The black rectangles (dotted line) show the change in mean arterial blood pressure (MAP)
with time. The open rectangles (interrupted line) represent the mean dose of dopamine
administered. The open circles (solid line) show the mean heart rate. Hyperthermic isolated
limb perfusion was started at time point 0 and stopped after 1.5 hrs. as indicated by the large
closed triangle. Error bars represent standard deviation.
Figure 2 shows the trend of mean values for heart rate, mean arterial pressure and dopamine
requirements.Nitric oxide in isolated limb perfusion with TNF-a
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All patients developed a clinical picture of septic shock with hypotension, a significant increase in
heart rate and cardiac index and a drop in systemic vascular resistance. They all needed volume
resuscitation and dopamine in a dose of up to 6 mg/kg/min to maintain adequate blood pressure. Signs
of sepsis abated within 12 hours and all patients could be discharged from the intensive care unit within
two days following perfusion. Systemic TNF-a levels were very high during and immediately after the
perfusion; they returned to baseline levels within 8 hours.
The clinical picture of septic shock in these patients is attributed to leakage of r-TNF-a from the
perfusion circuit to the circulation of the patient, mainly through collateral blood flow. Leakage was
confirmed by adding I
131 -labeled albumin to the perfusate, up to 2% of which was subsequently
localized in the central circulation of the patients. All patients showed a clinically and statistically
significant rise in heart rate and cardiac index ( p < 0.01) and a decrease in mean arterial pressure and
systemic vascular resistance ( p < 0.01). The rise in TNF-a-levels was statistically significant in all
patients.
None of the patients showed any increase in nitrite or nitrate level at any time point. The mean
value of the sum of nitrite and nitrate following perfusion in the 8 patients was 24,4 mmol/L (SD 5,9
mmol/L, 95% CI 23,4 - 25,4 mmol/L). This did not differ significantly from the mean value in 26
healthy controls of 23,9 mmol/L (SD 9,7 mmol/L, 95% CI 20,0 - 27,8 mmol/L).
Discussion
Nitric oxide is synthesized from L-arginine by nitric oxide synthase in many different cell types
including endothelial cells. Two forms of nitric oxide synthase have been distinguished. In its
constituent, calcium-dependent form nitric oxide synthase enzymatically produces small quantities of
nitric oxide to act as an important modulator of vascular tone, in normal animals as well as in humans.
In some animal models excessive amounts of nitric oxide can be produced by induction of a second
type of nitric oxide synthase, the so-called cytokine-inducible nitric oxide synthase. Overproduction of
nitric oxide by stimulation of this alternative, calcium-independent pathway is considered to explain the
inappropriate vasodilation which is the hallmark of septic shock [8]. Endotoxin, but also cytokines like
TNF-a are believed to induce nitric oxide synthase, leading to a sustained release of nitric oxide and
catecholamine-refractory vasodilation. A rapidly expanding literature has implicated a role for
cytokine-inducible nitric oxide synthesis in the pathogenesis of septic shock in animal models. Il-1,
TNF-a and endotoxin induce nitric oxide synthase activity in vascular smooth muscle cells from rat
aorta in vitro [9]. Studies in mice have shown that the administration of anti-TNF-a antibodies
markedly reduces endotoxin-induced shock and nitric oxide synthesis in vivo [10]. Kilbourn and
coworkers have induced hypotension in dogs by administering recombinant human TNF-a. N
G-
monomethyl-L-arginine, a competitive inhibitor of nitric oxide formation from L-arginine, completely
reversed this fall in blood pressure, which reappeared after the administration of excess L-arginine.
Though levels of nitrite or nitrate were not measured directly, the authors conclude that excessive nitric
oxide production mediates the hypotensive effect of TNF-a [3].
The role of a cytokine-inducible nitric oxide synthase in human septic shock is less clear. Cytokine-
inducible nitric oxide synthase has been demonstrated in only a few human cell types in vitro, in
contrast to the abundance of animal cell types shown to have this activity. TNF-a failed to induce nitric
oxide in vascular smooth muscle cells from human saphenous vein [11]. On the other hand clinical
studies in human bacterial sepsis have shown signs of increased nitric oxide production and aChapter VI
84
correlation between the concentration of endotoxin in plasma, the plasma levels of nitrite and nitrate
and the severity of circulatory shock [12, 13]. Furthermore L-arginine analogues that block nitric oxide
production have been effective at increasing blood pressure in septic patients [14]. In patients treated
with interleukin-2 plasma concentrations of nitric oxide metabolites have been shown to rise
significantly [15]. On the other hand Ochoa and coworkers have described normal levels of nitrite and
nitrate in trauma patients even when they developed signs of sepsis [16, 17].
In this study we have looked at the mechanism of vasodilation in cancer patients, who were treated
with isolated limb perfusion with r-TNF-a and melphalan, by measuring plasma levels of TNF- a,
nitrite and nitrate. Our study has several limitations. First, it may well be argued that plasma levels of
nitrite and nitrate do not reliably reflect activation of the inducible form of nitric oxide synthase. Local
levels of nitric oxide may have been sufficiently increased to generate profound vascular effects
without producing a demonstrable rise of nitrite or nitrate in the plasma. Conclusive data would
perhaps require a combination of plasma levels with other parameters such as excretion of nitrate in
urine, nitric oxide levels in exhaled air, or accumulation of 
15N-nitrite and 
15N-nitrate in plasma and
urine following administration of 
15N-labeled arginine. It should be noted however, that most of the
scientific evidence for a pivotal role of nitric oxide in various types of vasodilation has been based on
the demonstration of elevated levels of nitrite and nitrate in plasma or serum [12, 13, 15, 16, 18, 19].
Moreover, alternatives to measurement of plasma levels of nitrite and nitrate, like measurement of
urinary excretion of nitrate, have not been shown to be better markers of the septic state. On the
contrary, Jacob and coworkers have found that in trauma patients the mean plasma nitrate
concentration on days with evidence of infection was significantly increased compared with days
without active infection; mean urinary excretion of nitrate was not increased on infected days as
compared with days without infection [17]. We feel that activation of the inducible nitric oxide
synthase by r-TNF-a would at least be partially reflected in a rise of serum levels of nitrite and nitrate.
Another limitation of our study is that we did not investigate the effect on hemodynamic parameters of
nitric oxide inhibitors like N
G-methyl-L-arginine. Although important scientifically, this was considered
to be unsuitable since it would imply treating our patients with two different investigational drugs: r-
TNF-a and a nitric oxide synthase blocker. Furthermore, hypotension and shock in these patients could
well be managed with conventional therapy and did not warrant the use of investigational drugs with
possible harmful side effects. Potential drawbacks of the use of non-selective nitric oxide synthase
blockers have been pointed out by a number of authors [20, 21, 22, 23, 24].
Our findings in human subjects show that despite very high TNF-a levels and distinct signs of sepsis
syndrome, increased nitric oxide-production could not be demonstrated in plasma. It is possible that, in
human subjects, the presence of endotoxin is mandatory to trigger excessive nitric oxide production,
despite high levels of TNF-a. The assumed absence of relevant amounts of endotoxin in our model may
also explain the relative mildness and short duration of the clinical syndrome; animal experiments have
shown that the toxicity of TNF-a is greatly enhanced in the presence of endotoxin. Endotoxin levels in
blood were not measured in our study. Alternatively, there may be a nitric-oxide-independent pathway
through which TNF-a induces vascular relaxation, possibly by direct activation of soluble guanylate
cyclase. The existence of such a pathway was postulated earlier by Beasley and coworkers on the basis
of their experiments in human vascular smooth muscle cells [11]. They could show that interleukin 1,
TNF-a, interferon-g and Escherichia coli lipopolysaccharide increased cyclic guanosine
monophosphate in human saphenous vein vascular smooth muscle cells and that this effect was not
reversed by adding L-arginine analogues. Moreover, analysis of nitric oxide synthase mRNA with theNitric oxide in isolated limb perfusion with TNF-a
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use of polymerase chain reaction indicated that levels of mRNA for inducible nitric oxide synthase
were low.
Alternatively, hypotension in the setting of isolated limb perfusion with TNF-a could also be
explained by the generation of cyclooxygenase products like prostacyclin. Bernard et al. could show
high levels of both prostacyclin and thromboxane A2-metabolites in a group of patients with sepsis
syndrome [25]. Calcitonin gene-related peptide is yet another possible mediator of hypotension in
sepsis. It is increased in patients with sepsis and has been shown to be the most potent vasodilator and
hypotensive agent in humans to date [26]. Adenosine triphosphate-regulated K
+ channels have also
been shown to be important mediators of vascular smooth muscle tone [27]. These channels are
activated by decreased intracellular adenosine triphosphate, by cytosolic acidosis and increased
cytosolic lactate, conditions that may well have occurred in our patients. Activation of adenosine
triphosphate-sensitive K
+ channels hyperpolarizes vascular smooth muscle and reduces Ca
2+ entry into
the cell, thereby inducing relaxation and vasodilation. These Ca
2+ channels can also be downregulated
by oxygen radicals produced by an oxidative burst of endothelial cells in response to the presence of
endotoxin [28].
In conclusion, the results presented in this study do not support an important role for nitric oxide in
producing vasodilation and shock in cancer patients treated with isolated limb perfusion with r-TNF-
a, in whom a considerable leak of r-TNF-a from the perfusion circuit leads to high systemic levels of
this cytokine. Further studies will be needed to clarify the exact mechanism of septic vasodilation in
these patients.
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Chapter VII
Summary and concluding remarks
The main function of tumor necrosis factor alpha (TNF-a), a small polypeptide shared by all
mammals, is probably protection against invading bacteria, parasites and viruses; killing of these
microorganisms is facilitated in the presence of TNF-a. However, as its name suggests, TNF-a is also
capable of killing tumor cells, in vitro as well as in vivo. This unique capacity has focused the attention
on a possible role for this cytokine in the treatment of human cancer. It soon became apparent that its
usefulness as such is seriously limited by its toxicity. In sensitive laboratory animals administration of
even a very low dose of TNF-a will induce a sepsis like state, with hypotension, respiratory failure,
hepatic necrosis and renal insufficiency. Higher doses may be fatal. Human clinical trials with TNF-a
have confirmed its high toxicity, without showing any benefits in terms of tumor remissions.
Isolated limb perfusion was first described by Creech and Krementz in 1968. It is based on the
assumption that the circulation of a limb can be isolated completely from the rest of the circulation,
while the tissues of the isolated limb are kept viable with a perfusate, that is  oxygenated by a bubble
oxygenator. With a system like this, it would be possible to administer high concentrations of
antineoplastic drugs to tumors of a limb, while sparing the rest of the body the detrimental effects of
chemotherapy. Moreover, the temperature of the perfused limb could be maintained between 39 and
40
0C, which was expected to  increase the antitumor effect of most antineoplastic agents. Many
perfusions have been performed since, mainly with alkylating agents like melphalan, with variable
results.
Lejeune and coworkers were the first to try recombinant TNF-a (r-TNF-a) in such an isolated
perfusion system. They hoped to achieve sufficiently high concentrations of r-TNF-a in the tumor,
with a systemic toxicity that would remain manageable. In their experiments, r-TNF-a was combined
with melphalan, and with recombinant interferon gamma (r-IFN-g), a cytokine that enhances the
sensitivity of tumor cells to TNF-a by increasing the number of TNF-receptors on the cell surface. An
impressive remission rate was achieved, especially in patients with locally irresectable sarcoma of a
limb: 36% complete remissions and 51% partial remissions. In melanoma patients, the results also look
promising, but formal testing of the efficacy of isolated perfusion with r-TNF-a for melanoma has not
been completed. Systemic toxicity was manageable, but all patients required treatment in an intensive
care unit for symptoms of sepsis.
The studies presented in this thesis exclusively deal with systemic toxicity; they do not report on
remission- or survival rates. They were primarily undertaken to understand why patients treated
regionally with TNF- a developed such serious systemic complications. The effects of TNF-perfusion
on different organ systems are described in some detail. A better understanding of the toxicity of
isolated limb perfusion with r-TNF-a might contribute to a better management of patients treated in
this fashion. Because of the high remission rates that have been reported, their numbers can be
expected to increase.
Apart from being a promising technique to treat some types of cancer, isolated limb perfusion with
r-TNF-a presents an interesting model of sepsis and septic shock. In bacterial and fungal sepsis TNF-
a is universally considered to be one of the prime mediators of shock and organ dysfunction. Cell wall
products of these microorganisms, like lipopolysaccharide and peptidoglycan, stimulate macrophagesChapter VII
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to produce excessive amounts of TNF-a. TNF-a directly interferes with cellular function but also sets
of a cascade of inflammatory mediators that greatly enhance its deleterious effects. Clinical research of
sepsis has traditionally been hampered by late diagnosis: once the syndrome is diagnosed the
inflammatory cascade has fully developed and a plethora of damaging factors are at play. This makes
it difficult to determine the role of any factor in particular. In isolated perfusion with r-TNF-a we have
been able to show a considerable leak of r-TNF-a from the perfusion circuit to the general circulation.
In fact, this type of treatment amounts to a 90 min. intravenous infusion of high doses of r-TNF-a,
with a peak at the time when normal circulation is restored. Concentrations of systemic TNF-a are
many times higher in these patients than those found in healthy volunteers after administration of what
was considered to be  acceptable doses of r-TNF-a. The pathology of the sepsis syndrome, induced by
this cytokine, can thus be observed right from the start. Within its limitations, the model of isolated
limb perfusion with r-TNF-a might prove useful in the study of sepsis.
In Chapter I the clinical experience with r-TNF-a in the treatment of cancer is described. The
purpose of this chapter is to familiarize intensive care staff with the concept of isolated limb perfusion
with r-TNF-a, a new modality in cancer treatment, that has attracted considerable attention. The
systemic toxicity of this type of treatment, and of cancer therapy with r-TNF-a in general, is reviewed.
This review is based on Phase I and Phase II trials published in the English language, along with
supportive documentation and data on 64 patients treated with r-TNF-a in our own institution.
Guidelines are offered for the successful management of this type of patient. Treatment with r-TNF-a
results in a characteristic clinical syndrome, which resembles the sepsis syndrome. Hypotension and
respiratory failure are the main features of this syndrome. Toxicity is largely independent of the route
of administration. Very high serum concentrations of TNF-a, if short-lived, can be less toxic than
sustained low serum concentrations. Treatment of patients who have undergone isolated limb perfusion
with high dose r-TNF-a is feasible and effective in a modern ICU setting, even if high serum
concentrations of TNF-a, due to leakage from the perfusion circuit, cannot be avoided. Most patients
can be discharged from the ICU within 24 hours.
Chapter II describes the post-operative course of 25 consecutive patients, who underwent
hyperthermic isolated limb perfusion with r-TNF-a and melphalan, following pretreatment with r-INF-
g, as treatment for recurrent melanoma, primary nonresectable soft tissue tumors, planocellular
carcinoma or metastatic carcinoma. It is a retrospective, descriptive study, relating systemic TNF-a
levels with indices of disease severity. All patients developed features of sepsis syndrome and required
intensive care treatment. Most patients recovered quickly with a median ICU stay of 2 days (range 1-
25). Maximum systemic TNF-a levels ranged from 2284 to 83000 ng/L (median 25409 ng/L) and
returned to baseline values within 8 hours. Despite these high levels of TNF-a no patient died in the
ICU, although the patient with the highest TNF-a level developed multiple organ failure and required
continuous venovenous hemofiltration for 16 days. Linear regression analysis showed a positive
correlation between maximum TNF-a levels and systemic vascular resistance (p<0.01), cardiac index
(p<0.02), lung injury score (p<0.02), prothrombin time (p<0.02) and activated partial thromboplastin
time (p<0.05). It is concluded that hyperthermic isolated limb perfusion with r-TNF-a leads to high
systemic levels of TNF-a, probably due to leakage of r-TNF-a from the perfusion circuit, mainly
through collateral bloodflow. A sepsis like syndrome is seen in all patients. Despite high levels of
systemic TNF-a, this sepsis syndrome is short-lived and recovery is rapid and complete in most
patients. Summary and concluding remarks
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Several investigators have reported that IFN-g can alter TNF-a-induced effects in vitro. In Chapter III
we have assessed in vivo effects of r-IFN-g on r-TNF-a-induced activation of systemic blood coagulation in
a non-randomized study in 20 consecutive cancer patients. Eight patients were treated with r-IFN-g prior to
and during hyperthermic isolated limb perfusion with r-TNF-a and melphalan (IFN-g group). They were
compared with twelve patients who did not additionally receive r-IFN-g (non-IFN-g group). Before start of
perfusion, higher levels of TNF-a, prothrombin fragment 1 and 2 (F1+2) and thrombin-antithrombin
complexes (TAT) were found in the IFN-g group. Fibrinogen and antithrombin III (ATIII) levels tended to be
lower in this group. High TNF-a levels, due to leakage during perfusion, were associated with activation of
coagulation in all patients, that became obvious after the end of perfusion, when heparin treatment had been
antagonized. Activation, measured by increased F1+2 and TAT levels, was significantly stronger in the IFN-g
group. Monocytic tissue factor (TF) remained low, possibly due to shedding of TF positive vesicles and/or
sequestration of TF positive activated monocytes against the vessel wall. In both groups F1+2 and TAT levels
declined 24 hours after the perfusion, whereas monocytic TF increased to levels that were higher in the IFN-g
group. In conclusion, our data confirm a strong activation of coagulation induced by r-TNF-a in cancer
patients. They suggest that r-IFN-g may lead to a slight activation of coagulation and augments TNF-a
induced procoagulant activity. These effects may be due to r-IFN-g induced sustained monocytic TF activity.
The study described in Chapter IV was undertaken to determine the effects on systemic
fibrinolysis of hyperthermic isolated limb perfusion with r-TNF-a and melphalan, with or without
pretreatment with r-IFN-g. Twenty patients were treated with r-TNF-a and melphalan; four patients,
treated with melphalan only, served as controls. Of the twenty patients treated with both r-TNF-a and
melphalan, eight received r-IFN-g for two days before the perfusion and as a bolus into the perfusion
circuit. A significant leak of r-TNF-a from the perfusion circuit to the systemic circulation was
observed in all r-TNF-a treated patients (mean maximum TNF-a 87227 ng/L versus 31 ng/L in
controls, p<0.002). In these patients, but not in controls, there was an almost instantaneous rise in
systemic tissue plasminogen activator (t-PA) activity (from 0.26 IU/ml to 5.28 IU/ml in 90 min),
causing activation of fibrinolysis. After a delay of 90 minutes, plasminogen activator inhibitor-1 (PAI-
1) antigen rose to high levels in the r-TNF-a treated group (mean maximum PAI-1 1652 ng/ml versus
211 ng/ml in controls, p<0.02), associated with a sharp decrease of tPA-activity and a slower decrease
of plasminogen-antiplasminogen complexes (from 5.28 IU/ml to 0.02 IU/ml in 2 h, and from 1573
mg/L to 347 mg/L in 22 h respectively). No additional effect of r-IFN-g pretreatment on fibrinolysis
could be demonstrated. These results suggest that in isolated limb perfusion with r-TNF-a and
melphalan an initial activation of systemic fibrinolysis, induced by leakage of r-TNF-a from the
perfusion circuit, is set off by a subsequent inhibition of the fibrinolytic system by PAI-1. This large
increase in PAI-1 could place the patient at risk for deposition of microthrombi in the systemic
circulation.
Chapter V describes renal function parameters in 11 cancer patients, who underwent 12
perfusions. Three patients, perfused with melphalan only, served as controls. All patients treated with
r-TNF-a developed a sepsis syndrome and needed volume replacement and inotropes to remain
normotensive; controls had an uneventful postoperative course. Creatinine clearance decreased
transiently on the day of perfusion in both groups (mean preperfusion clearance 118 ml/min, mean
postperfusion clearance 68 ml/min, p<0.02, n=15). Follow-up measurements of renal plasma flow and
glomerular filtration rate in 9 r-TNF-a treated patients did not suggest permanent damage. One patient
became hypotensive and developed transient multiple organ dysfunction with renal failure needing
hemofiltration. In r-TNF-a treated patients, but not in controls, a transient increase in clearance of b2Chapter VII
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microglobulin (49 vs. 8171 ml/min, p<0.001) and urinary excretion of phosphate (12 vs. 48 mmol/24
hrs, p<0.05) was seen, compatible with proximal tubular dysfunction. These data suggest that
hyperthermic isolated limb perfusion with melphalan decreases glomerular function, whether or not r-
TNF-a is added to the perfusion circuit. Extension of the treatment regimen with r-TNF-a may result
in additional proximal tubular dysfunction. If hypotension can be avoided this deterioration in renal
function seems to be transient, with full recovery within weeks.
Finally, Chapter VI aims to analyze the mechanism of vasodilation and circulatory shock in
patients who are treated with isolated limb perfusion with melphalan and r-TNF-a for locally advanced
malignant tumors. The role of nitric oxide, if any, was determined by measuring plasma nitrite and
nitrate levels. Eight consecutive patients developed sepsis syndrome due to leakage of r-TNF-a from
the perfusion circuit to the systemic circulation. Despite the presence of very high systemic TNF-a
levels during and immediately after perfusion and definite signs of hyperdynamic circulatory shock
(increased heart rate, increased cardiac index, decreased systemic vascular resistance) nitrite and
nitrate levels, measured in plasma at several time points, were not elevated. The hypothesis that, in
humans, TNF-a induces vasodilation and shock through activation of inducible nitric-oxide synthase
and subsequent formation of excessive quantities of nitric oxide is not substantiated by our results.
Normal nitric oxide metabolite levels were found in the presence of high TNF-a levels and shock.
Other mechanisms that do not involve the nitric oxide pathway are likely to play a role in the
generation of hypotension and septic shock in this setting
The experience with isolated limb perfusion with r-TNF-a, laid down in this thesis, has confirmed
the feasibility of this type of treatment. The question whether r-TNF-a has a role in anticancer therapy
has not been specifically addressed in this work. However, it can be assumed that the usefulness of r-
TNF-a as an antineoplastic agent will be favorably influenced if its therapeutic index could be
increased. Improvement of postoperative care is one way to achieve this. We speculate that with the
current standard of anesthesia and postoperative intensive care, even higher dosages of r-TNF-a than
have been studied thus far, can be tolerated by most patients. For treatment of malignancies not located
on a limb, intravenous administration of r-TNF-a in dosages exceeding what has been considered the
maximum tolerable dose (300 mg/m
2 over 30 min.) can be considered. Even more important will be the
quest for safer TNFs; mutant TNFs that selectively bind to the 55 kd TNF-receptor (TNF-R1) share
the anticancer potential of native TNF-a but have less pro-inflammatory activity.
Finally, basic research in sepsis will eventually supply us with drugs that can abrogate many of its
deleterious effects. These drugs will be equally effective to counteract systemic toxicity in cancer
treatment with r-TNF-a. The challenge here will be to reduce toxicity without reducing antitumor
efficacy. Conversely, drugs that reduce toxicity in a model of isolated perfusion with r-TNF-a may be
useful in the treatment of sepsis.Samenvatting en conclusies
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Chapter VIII
Samenvatting
Tumor necrosis factor alpha (TNF-a) is een klein eiwit dat bij alle zoogdieren voorkomt. Het heeft een
functie in de afweer tegen bacteriën, virussen en parasieten. Zodra deze organismen het lichaam
binnentreden gaan bepaalde afweercellen TNF-a produceren. Daarnaast lijkt het ook een stof te zijn
waarmee het lichaam zich beschermt tegen kanker. Al in de vorige eeuw bereidde de chirurg William
Coley aftreksels van bacteriën,waarmee hij ongeneeslijk zieke kankerpatiënten inspoot: bij een aantal
van hen zag hij na deze behandeling een sterke teruggang in grootte van de gezwellen. Helaas was het
middel soms erger dan de kwaal. Toch bleef de gedachte dat bacteriën, direct of indirect, een factor
tegen kanker konden produceren onderzoekers bezighouden. In 1975 lieten Carswell en zijn
medewerkers zien dat muizen, die werden ingespoten met endotoxine (een bestanddeel van de celwand
van sommige bacteriën) een stof in hun bloed maakten, die werkzaam was tegen kanker. Wanneer
bloed van deze muizen werd ingespoten bij andere muizen, die een gezwel in de huid hadden, zagen de
onderzoekers die gezwellen verdwijnen. Zij concludeerden hieruit dat inspuiten van celbestanddelen van
bacteriën aanleiding geeft tot de vorming van een (overdraagbare) stof die een tumor-dodende werking
heeft. Deze stof, waar ook Coley’s resultaten voor een belangrijk deel aan moeten worden
toegeschreven, noemden zij “tumor necrosis factor”. Met het vorderen van de biologische technologie
werd het uiteindelijk mogelijk het TNF-a zuiver in handen te krijgen en bovendien in voldoende
hoeveelheden om er experimenten bij mensen mee uit te voeren.
De resultaten van de eerste experimenten met TNF-a bij mensen vielen echter tegen. De meeste
patiënten werden ernstig ziek na toediening van het middel en maar zelden werd een gunstige reactie op
het gezwel gezien. Waarschijnlijk waren er nog hogere doseringen TNF-a nodig om effect op de
kwaadaardige gezwellen te kunnen hebben, maar dergelijke doseringen werden voor de mens te giftig
geacht. De verschijnselen die deze patiënten toonden deden overigens sterk denken aan wat men kon
waarnemen bij patiënten die een ernstige infectie doormaakten. Inmiddels was komen vast te staan dat
TNF-a een centrale rol speelt in de reactie van het lichaam op een ernstige infectie. Het fungeert
daarbij als pro-inflammatoir eiwit, hetgeen wil zeggen dat het aan het begin staat van een cascade van
stoffen die ontstekingsverschijnselen geven. Bij een ernstige infectie produceert het menselijk lichaam
grote hoeveelheden TNF-a, waarschijnlijk meer dan nuttig is voor de afweer tegen de binnendringende
microorganismen. De toestand die dan ontstaat wordt aangeduid als “sepsis”, en wordt gekenmerkt
door een lage bloeddruk, een verminderde hartwerking en onvoldoende bloeddoorstroming van de
organen. Deze symptomen worden ook gezien bij kankerpatiënten die met hoge doseringen TNF-a
worden behandeld.
TNF-a raakte als kankerbestrijdend middel op de achtergrond totdat Lejeune en zijn medewerkers
besloten het op een andere manier toe te passen. Zij maakten daarbij gebruik van het principe van
geïsoleerde regionale perfusie. Deze techniek was al eerder toegepast, maar nog niet met TNF-a. Het
principe van geïsoleerde perfusie is eenvoudig: door de bloedsomloop van een arm of van een been
volledig te scheiden van de bloedsomloop van de rest van het lichaam is het mogelijk gezwellen aan
armen of benen met hoge doseringen geneesmiddelen te behandelen, zonder dat de rest van het lichaam
te lijden heeft onder de giftigheid van die middelen. Zo’n volledige isolatie wordt bereikt door de
aanvoerende en de afvoerende bloedvaten van een arm of een been aan te sluiten op een hart-longChapter VIII
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machine, die het bloed in de geïsoleerde extremiteit niet alleen rondpompt maar ook van zuurstof
voorziet (zie afbeelding bladzijde 12) Aan dit geïsoleerde circuit kunnen dan hoge doseringen
geneesmiddelen worden toegediend. Lejeune en zijn medewerkers waren de eerste die daar, naast de
gewone middelen tegen kanker, TNF-a aan toevoegden. Omdat dit keer wel hoge doseringen konden
worden gebruikt (de bloedsomloop van het lidmaat was immers ontkoppeld van de rest van het
lichaam) waren de effecten op bepaalde vormen van kanker veel beter dan in vroegere experimenten.
Tegelijk bleek echter dat de patiënten ook van dit type behandeling ernstig ziek werden, zij het dat hun
ziekteverschijnselen niet lang duurden en goed te behandelen waren op een Intensive Care afdeling.
Dit proefschrift bevat een aantal artikelen waarin beschreven wordt wat er met de patiënt gebeurt
tijdens zo’n geïsoleerde perfusie met TNF-a. De effecten van deze behandeling op het gezwel vormen
geen onderwerp van dit onderzoek.
In Hoofdstuk I wordt een overzicht gegeven van de ervaring die is opgedaan met TNF-a als anti-
kanker middel. De nadruk ligt daarbij op de geïsoleerde perfusietechniek. Het overzicht is zowel op
literatuurgegevens gebaseerd als op de eigen ervaring met een serie van 64 perfusiepatiënten. Alle
patiënten, die zo’n behandeling ondergingen toonden dezelfde verschijnselen, zij het dat de ernst van
patiënt tot patiënt varieerde. Lage bloeddruk en falen van de ademhaling waren de belangrijkste
kenmerken. Met moderne Intensive Care mogelijkheden konden bijna alle patiënten, die een geïsoleerde
perfusie met TNF-a hadden ondergaan de dag na de operatie weer worden teruggeplaatst naar de
gewone verpleegafdeling. De manier van toedienen van het TNF-a maakt voor de bijwerkingen
overigens weinig uit: ernstige algemene vergiftigingsverschijnselen zijn niet alleen beschreven wanneer
TNF-a via de bloedbaan wordt ingespoten, maar ook bij onderhuidse toediening, bij toediening in de
spier en bij toediening rechtstreeks in het gezwel.
In Hoofdstuk II wordt het ziektebeloop van 25 perfusiepatiënten meer in detail beschreven. Het
bleek dat tijdens en direct na de perfusie een deel van de ingespoten TNF-a uit het geïsoleerde lidmaat
weglekte naar de centrale bloedsomloop. In het bloed werden daarbij concentraties van TNF-a gemeten
die vele malen hoger waren dan de concentraties die bij ernstige bacteriële infecties worden
aangetroffen. Binnen 24 uur was de concentratie overigens weer tot normale waarden gedaald. Ook de
klinische verschijnselen waren dan grotendeels voorbij. Uit eerder onderzoek is bekend dat TNF-a tot
vaatverwijding leidt, de long beschadigt en de stollingsneiging van het bloed vergroot. In het onderzoek
dat in dit hoofdstuk wordt beschreven kon worden aangetoond dat er een verband bestaat tussen de
hoogte van de gemeten TNF-a concentratie in het bloed (dus de mate van lekkage) enerzijds, en de
vaatverwijding, longbeschadiging en stollingsactiviatie anderzijds. Uit het onderzoek wordt
geconcludeerd dat tijdens geïsoleerde perfusie met TNF-a ook in de rest van de bloedsomloop hoge
concentraties TNF-a worden gevonden, en dat dit waarschijnlijk wordt verklaard door lekkage vanuit
het niet volledig geïsoleerde lidmaat of door nog vrijkomen van TNF-a uit de extremiteit na herstel van
de circulatie. Door deze lekkage treedt een ziektebeeld op dat sterke gelijkenis vertoont met een ernstige
bacteriële infectie, maar korter duurt. Met adequate zorg herstellen de meeste patiënten binnen 24 uur.
In Hoofdstuk III wordt nader ingegaan op de activatie van de stolling die optreedt wanneer
patiënten worden behandeld met regionale perfusie met TNF-a. Er wordt een vergelijking gemaakt
tussen 8 patiënten die naast melfalan en TNF-a ook nog interferon-gamma (IFN-g) kregen en 12
patiënten die alleen melfalan en TNF-a ontvingen. Van IFN-g is bekend dat het de werking van TNF-a
op gezwellen versterkt. Uit het onderzoek blijkt dat de IFN-g groep, die twee dagen voor de perfusie
was gestart met onderhuidse toediening van IFN-g, direct voorafgaand aan de perfusie al tekenen van
een geactiveerde stolling had. Tijdens de perfusie trad er in beide groepen een sterke activatie van deSamenvatting en conclusies
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stolling op, maar deze was meer uitgesproken in de IFN-g-voorbehandelde groep. In het hoofdstuk
wordt de veronderstelling geopperd dat toediening van IFN-g een bepaald type witte bloedcel, de
monocyt, aanzet tot het produceren van “tissue factor”, een stof die de stollingscascade in gang zet.
Hoofdstuk IV behandelt de effecten van geïsoleerde perfusie met TNF-a op het afbreken van
stolsels: de fibrinolyse. De verhouding tussen stolling en fibrinolyse wordt bij gezonde individuen zo
geregeld, dat er enerzijds geen spontane bloedingen optreden en er anderzijds geen vaatafsluitingen
ontstaan door spontane stolselvorming. In Hoofdstuk III was al beschreven dat bij perfusiepatiënten de
stolling geactiveerd is. In Hoofdstuk IV wordt een groep van 20 patiënten, die werd behandeld met
melfalan en TNF-a vergeleken met een controlegroep die alleen melfalan in het perfusiecircuit kreeg
toegediend. De TNF-a behandelde groep toonde tijdens perfusie een snelle stijging van het “tissue
plasminogen acitvator” (t-PA), een eiwit dat de fibrinolyse activeert. Een dergelijke t-PA stijging werd
niet gezien in controlepatiënten, die een perfusie met alleen melfalan ondergingen. Enige tijd na deze
stijging werd in de TNF-a behandelde groep echter een veel grotere stijging van het “plasminogen
activator inhibitor” (PAI-1) gezien, een verbinding die het t-PA en daardoor de fibrinolyse remt. In
Hoofdstuk IV wordt de suggestie geopperd dat door deze sterke remming van de stolselafbraak,
gevoegd bij de al eerder aangetoonde activering van de stolling, een verhoogd risico op trombose en
vaatafsluiting kan ontstaan bij patiënten, die behandeld worden met een TNF-a perfusie.
In Hoofdstuk V wordt onderzocht wat de invloed van perfusie met TNF-a op de nierfunctie is. Uit
dierproeven was al bekend dat inspuiten van TNF-a vaak tot nierinsufficiëntie aanleiding geeft.
Daarbij is het niet duidelijk of de nier nu wordt beschadigd door de lage bloeddruk die ontstaat na
toediening van TNF-a of dat er ook sprake is van een direct toxisch effect van TNF-a op de nier. In dit
hoofdstuk worden 11 patiënten, die werden behandeld met melfalan en TNF-a vergeleken met 3
controlepatiënten, die alleen melfalan in het perfusiecircuit kregen toegediend. In beide groepen werd
op de dag van perfusie een verslechtering van de nierfunctie waargenomen die dus kennelijk moet
worden toegeschreven aan de procedure en niet aan de TNF-a. Bij een aantal patiënten werd de
nierfunctie ook nog nauwkeuriger gemeten met behulp van radioactief gemaakte stoffen. Deze techniek
laat toe iets te zeggen over de bloeddoorstroming van de nier (“renal plasma flow) en de
filtratiewerking (“glomerular filtration rate”). Er bleken geen belangrijke verschillen te bestaan tussen
vóór en na perfusie gemeten waarden, zodat kon worden geconcludeerd dat er geen blijvende schade
aan de nieren was ontstaan als gevolg van de perfusie met TNF-a. Het is van belang hierbij te
vermelden dat bij alle patiënten de bloeddruk op peil kon worden gehouden, behalve bij één patiënt, die
uiteindelijk een nierinsufficiëntie ontwikkelde. Aanvullend werd nog gekeken naar de urine uitscheiding
van b2 microglobuline, een eiwit dat in de normale situatie na filtratie bijna volledig wordt
teruggeresorbeerd in de nierbuizen. In de met TNF-a behandelde groep nam de uitscheiding van dit
eiwit sterk toe, in tegenstelling tot datgene wat in de controlegroep werd gezien. Dit zou kunnen wijzen
op een tijdelijke beschadiging van het eerste gedeelte van de nierbuizen (de proximale tubuli) door
TNF-a.  Samenvattend is de conclusie van dit hoofdstuk dat geïsoleerde perfusie met TNF-a wat de
nierfunctie betreft goed wordt verdragen en dat TNF-a mogelijk een specifiek beschadigend effect heeft
op de proximale tubuli.
Tenslotte wordt in Hoofdstuk VI onderzoek gepresenteerd dat probeert opheldering te verschaffen
over het mechanisme van de vaatverwijding die wordt gezien bij geïsoleerde perfusie met TNF-a. In
proefdieren is aannemelijk gemaakt dat TNF-a een vaatwand enzym kan aanzetten (het “nitric oxide
synthase”), dat het aminozuur arginine omzet in het citrulline. Hierbij komt een kort levende, maar zeer
reactieve stof vrij, het nitric oxide (NO). Dit NO werkt ontspannend op de gladde spieren in deChapter VIII
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vaatwand en leidt zo tot sterke vaatverwijding. Of het TNF-a bij de mens soortgelijke effecten heeft is
minder bekend. In het perfusiemodel worden hoge concentraties TNF-a gevonden terwijl er ook
meestal sprake is van vaatverwijding. Om deze reden is gezocht naar aanwijzingen voor overmatige
NO-productie bij deze patiënten. Omdat NO vluchtig is, werden metingen verricht van nitriet en
nitraat, de stabiele omzettingsproducten van NO. Bij geen van de 8 onderzochte patiënten kon een
toename van nitriet of nitraat worden aangetoond, terwijl er wel degelijk sprake was van
vaatverwijding en lage bloeddruk. In Hoofdstuk VI wordt dan ook geconcludeerd dat de vaatverwijding
die ontstaat onder invloed van TNF-a perfusie niet via vorming van NO loopt. Het precieze
mechanisme is nog onbekend.
Het onderzoek dat in dit proefschrift is beschreven onderstreept nog eens dat behandeling van
kankerpatiënten met geïsoleerde regionale perfusie met TNF-a goed uitvoerbaar is. De patiënten
worden weliswaar ziek, met symptomen die doen denken aan een ernstige bacteriële infectie, maar met
goede zorg herstellen zij over het algemeen snel en volledig. Op grond van de ervaring opgedaan met
dit type behandeling kan de veronderstelling worden geuit dat, met moderne behandelingsmethoden, een
hogere dosering TNF-a verdragen kan worden dan tot nog toe werd aangenomen. Misschien moet zelfs
worden overwogen de eerder uitgevoerde experimenten met in de bloedvaten toegediende TNF-a te
herhalen, maar dan met hogere doseringen en in volledig gecontroleerde omstandigheden
Op grond van de overeenkomsten die er bestaan tussen patiënten, die een ernstige infectie
doormaken en patiënten, die met TNF-a perfusie worden behandeld, lijkt het waarschijnlijk dat
geneesmiddelen die werkzaam blijken te zijn op het gebied van sepsis ook werkzaam zullen blijken op
het terrein van perfusie en vice versa. Onderzoek bij patiënten, die met TNF-a perfusie worden
behandeld, zoals beschreven in dit proefschrift, kan op die manier een bijdrage leveren aan het
vergroten van inzicht in het mechanisme van ontsteking, waardoor uiteindelijk betere
behandelingsmogelijkheden  voor sepsis beschikbaar zullen komen.95
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